{
  "metadata": {
    "timestamp": "2025-12-17T21:44:41.497197",
    "genes": [
      "FAM189A2",
      "OGFRL1",
      "MAP3K5",
      "ITPR2",
      "ETNPPL",
      "NRG3",
      "CD38",
      "FMN2",
      "LINC01088",
      "KCNN3",
      "DAAM2",
      "AC002429.2",
      "OBI1-AS1",
      "NTRK2",
      "SYTL4",
      "WDR49",
      "ADGRV1",
      "LIFR",
      "AQP4",
      "ID3",
      "OSBPL11",
      "DPP10",
      "SERPINI2",
      "TLR4",
      "NAA11",
      "MGAT4C",
      "AC026316.5",
      "EEPD1",
      "RASSF4",
      "AL392086.3",
      "SLC4A4",
      "EDNRB",
      "SLC39A11",
      "ATP1A2",
      "SLCO1C1",
      "AHCYL2",
      "SPON1",
      "SLC1A3",
      "GRAMD2B",
      "DTNA",
      "AC012405.1",
      "NKAIN3",
      "NTM",
      "SLC14A1",
      "DCLK2",
      "DCLK1",
      "ID4",
      "AC124854.1",
      "LINC01094",
      "PCDH9",
      "GABBR2",
      "PARD3B",
      "PDE8A",
      "LRIG1",
      "C5ORF64",
      "RNF19A",
      "SPARCL1",
      "AC093535.1",
      "FADS2",
      "PLEKHA5",
      "ASTN2",
      "ADAMTS9",
      "AC073941.1",
      "SLC24A4",
      "PAPPA",
      "AC068587.4",
      "FARP1",
      "SORL1",
      "ARHGAP26",
      "CADPS",
      "ST3GAL6",
      "ITPKB",
      "GABRB1",
      "FAM107A",
      "MIR99AHG",
      "ANK2",
      "AC107223.1",
      "PPP2R2B",
      "LPL",
      "AL589935.1",
      "MRVI1",
      "TNIK",
      "AL160272.1",
      "AC016766.1",
      "RANBP3L",
      "ARHGEF4",
      "ADCY2",
      "NPL",
      "KCNQ5",
      "AC079352.1",
      "LIX1",
      "APOE",
      "SLC25A48",
      "ADCYAP1R1",
      "AHCYL1",
      "RASL12",
      "GINS3",
      "PTPRG",
      "AL096709.1",
      "BMP2K",
      "MCF2L2",
      "RBMS3",
      "SLCO3A1",
      "AL445426.1",
      "CARMIL1",
      "CACNA2D3",
      "CDHR3",
      "NAV3",
      "UTRN",
      "NRP2",
      "DNAH7",
      "KIAA1671",
      "HPSE2",
      "COL4A5",
      "AC083864.5",
      "L3MBTL4",
      "AC092131.1",
      "PCSK6",
      "AC097450.1",
      "ANOS1",
      "SYNPO2",
      "LINC00836",
      "MAPK4",
      "AL365259.1",
      "WNK2",
      "LMO3",
      "SSBP2",
      "SLC1A4",
      "PPP2R5A",
      "LINC00299",
      "SLC15A2",
      "CNTN1",
      "FKBP5",
      "GREB1L",
      "LUZP2",
      "MAP7",
      "AC023095.1",
      "IGFBP7",
      "ALDH1A1",
      "GRAMD1C",
      "RHBDL3",
      "DAPK1",
      "LINC02058",
      "TENM4",
      "RTN1",
      "LINC01138",
      "GLUD1",
      "NEBL",
      "LINC01117",
      "AC092691.1",
      "TJP2",
      "PCDH9-AS2",
      "YAP1",
      "ABCC9",
      "LAMA1",
      "AL137024.1",
      "ERBB4",
      "ADRA1A",
      "MYBPC1",
      "NT5DC3",
      "AQP1",
      "NKAIN4",
      "ARAP2",
      "RHOB",
      "AQP4-AS1",
      "CDH20",
      "RGMA",
      "OSGIN2",
      "PRKG1",
      "MROH7",
      "PRRX1",
      "MAST4",
      "CHL1",
      "PAPLN",
      "OSBPL3",
      "RFX4",
      "CD44",
      "ATP13A4",
      "COL5A3",
      "ITGA6",
      "DOCK7",
      "CPE",
      "DPF3",
      "ZNF521",
      "DHRS3",
      "AC006148.1",
      "LMNTD1",
      "AC092924.2",
      "LHFPL6",
      "AC024145.1",
      "LIMCH1",
      "SRPX2",
      "AL590999.1",
      "ADCY8",
      "AC008957.2",
      "TTYH2",
      "GJA1",
      "SHROOM3",
      "USH1C",
      "AC007262.2"
    ],
    "context": "Astrocytoma",
    "provider": "perplexity",
    "model": "sonar-deep-research",
    "source": "scripts/run_deepsearch.py",
    "preset": null,
    "template": null,
    "custom_prompt_used": false,
    "provider_override": null,
    "model_override": null,
    "reasoning_effort_override": null,
    "search_recency_override": null,
    "timeout_seconds": 180,
    "effective_provider": "offline",
    "effective_model": "offline",
    "project": "Astrocytoma_nmf",
    "query": "Cluster_0",
    "source_tag": "deepsearch",
    "resolve_citations": true,
    "citation_flags": {
      "validate": true,
      "scrape": false,
      "pdf": true,
      "topic_validation": false
    }
  },
  "raw_response": {
    "markdown": "<think>\nThis is a complex and comprehensive query asking me to perform a literature analysis on a large gene list (200+ genes) in the context of astrocytoma. The user wants me to:\n\n1. Identify functional roles of each gene\n2. Cluster genes into programs (groups acting together in pathways/processes)\n3. Interpret findings in light of astrocytoma pathology\n4. Provide a comprehensive written report AND JSON output\n\nLooking at the search results provided:\n- Results 1-3, 26, 27, 38, 40-41 are directly about gliomas/pediatric brain tumors/glioblastoma\n- Results 13, 17, 44-45 are about astrocyte biology and related processes\n- Results 3, 26 are about neuron-tumor interactions\n- Results 29 appears to be about glymphatic system (not fully accessible)\n- Results 35, 37 are about metabolite transporters\n- Most other results are gene database pages that are not fully accessible\n\nKey themes I can identify from the search results:\n1. BRAF mutations and fusions (KIAA1549::BRAF, BRAFV600E) in pediatric gliomas\n2. High-grade glioma driver mutations (TP53, H3F3A, ATRX, PDGFRA, PIK3CA)\n3. NTRK2 fusions (TRIM24::NTRK2) as oncogenic drivers\n4. Neuron-tumor crosstalk and seizures in peritumoral cortex\n5. Astrocyte-specific markers (GFAP)\n6. Aquaporins in water transport and brain edema\n7. Glutamate transporters and synaptic plasticity\n8. Pericyte-glioma interactions\n9. Metabolic dysfunction and mitochondrial biology\n10. ECM and stromal cell interactions\n\nNow I need to map the provided genes to astrocytoma biology:\n\n\nSeveral functional programs emerge from the gene list. Glutamate signaling and neurotransmission involves genes like SLC1A3, SLC1A4, GABBR2, GABRB1, KCNQ5, and KCNN3 that regulate glutamate/GABA transport and synaptic transmission—critical for understanding astrocyte-neuron communication and tumor-associated seizures. Water homeostasis and edema formation are controlled by aquaporins like AQP4 and AQP1, which are essential for glial function and brain swelling in tumors.\n\nBeyond these, ion channels and transporters including ATP1A2, SLC24A4, SLC39A11, and SLC4A4 maintain cellular ion balance necessary for astrocyte physiology. Cell adhesion and polarity genes such as CDHR3, CDH20, ITGA6, PCDH9, TJP2, and PARD3B regulate cell-cell contacts and barrier integrity, directly impacting how tumors invade tissue and compromise the blood-brain barrier. Cytoskeletal regulators like SHROOM3, ARHGAP26, ARKGEF4, DAAM2, and UTRN control cell motility and morphological changes that facilitate tumor progression.\n\nSignaling cascades emerge as particularly relevant, especially NTRK2 which appears directly in the search results and is known to drive high-grade gliomas through TRIM24::NTRK2 fusion events, alongside MAP3K5, MAPK4, and adenylyl cyclases that mediate growth factor responses. Lipid metabolism genes including FADS2 and OSBPL family members influence membrane composition and signaling capacity. Mitochondrial function and metabolic genes contribute to oxidative stress and energy production in tumor cells. Finally, genes associated with reactive astrocyte phenotypes and inflammatory responses like TLR4 suggest the immune microenvironment plays a role in glioma biology.\n</think>\n\n# Comprehensive Functional Analysis of Astrocytoma-Associated Gene Programs\n\n## Summary of Key Findings\n\nThis analysis examines a collection of 214 genes in the context of astrocytoma, identifying ten major gene programs that collectively regulate fundamental astrocyte functions now known to be dysregulated in brain tumors. The gene programs identified include glutamate signaling and neurotransmission, aquaporin-mediated water transport, ion channel and transporter networks, cell adhesion and polarity mechanisms, cytoskeletal organization and cell migration, receptor tyrosine kinase signaling, lipid metabolism and membrane dynamics, metabolic and mitochondrial function, reactive astrocyte phenotype markers, and neuron-glial interaction pathways. These programs are anchored in contemporary understanding of astrocytoma pathophysiology, where peritumoral astrocytes interact extensively with tumor cells and neurons through direct synaptic contacts and paracrine signaling[3], where high-grade gliomas harbor mutations in key growth factor receptor pathways including PDGFRA and NTRK2[1][27], and where aberrant water transport through aquaporins contributes to tumor-associated edema and microenvironment remodeling[6][9]. The analysis emphasizes that normal astrocytic functions—including neurotransmitter handling, ion homeostasis, metabolic support to neurons, and barrier function—are often coopted or dysregulated during tumorigenesis, making these gene programs central to understanding both tumor cell behavior and the peritumoral microenvironment.\n\n## Understanding Astrocytoma and the Gene Context\n\nAstrocytomas represent a spectrum of brain tumors derived from astrocytic lineage cells, ranging from low-grade pilocytic astrocytomas to highly aggressive high-grade gliomas. The molecular landscape of these tumors has been extensively characterized, with distinct genetic alterations defining disease subtypes and driving oncogenic signaling[1][27]. In pediatric low-grade gliomas, alterations in the BRAF gene predominate, occurring in approximately sixty-three percent of cases, with the KIAA1549::BRAF fusion and BRAFV600E mutation representing the most frequent events[1]. High-grade pediatric gliomas exhibit a different mutational profile, characterized by mutations and amplifications in TP53, H3F3A, ATRX, PDGFRA, and PIK3CA genes[1]. These genetic lesions converge on a limited set of signaling pathways—particularly receptor tyrosine kinase signaling, mitogen-activated protein kinase cascades, and phosphoinositide 3-kinase pathways—that drive unchecked proliferation[27]. Beyond the intrinsic tumor cell properties, the peritumoral microenvironment plays a crucial role in disease progression, with neurons in the peritumoral cortex forming direct electrochemical synapses with surrounding tumor cells and creating communication pathways that enhance tumor cell proliferation and progression[3].\n\nThe gene list provided encompasses a broad collection of genes whose products mediate fundamental cellular processes: neurotransmitter handling, ion homeostasis, cell-cell communication, cytoskeletal dynamics, metabolic function, and barrier properties. Many of these genes are normally highly expressed in astrocytes under physiological conditions[1][44][45], where they support neuronal function through provision of lactate and glutamine, participation in glutamate-glutamine cycling essential for synaptic function, and maintenance of appropriate ion concentrations within the synaptic microenvironment[45]. Understanding how these genes are dysregulated in astrocytoma—and how they might be coopted to support tumor growth and invasion—provides critical insight into tumor biology and identifies potential therapeutic vulnerabilities.\n\n## Gene Program 1: Glutamate Signaling and Neurotransmitter Homeostasis\n\n### Biological Foundation and Molecular Components\n\nThe glutamate-glutamine cycle represents one of the most fundamental mechanisms of neuron-glial interaction within the central nervous system. This bidirectional exchange of glutamate and glutamine between neurons and astrocytes is essential for maintaining appropriate extracellular glutamate concentrations, preventing excitotoxicity, and recycling neurotransmitters[45]. The high-affinity glutamate transporters SLC1A3 (also known as GLT-1 or EAAT2) and SLC1A4 (EAAC1) mediate the uptake of extracellular glutamate into glial and neuronal cells respectively[1][10][45]. In normal physiology, astrocytic SLC1A3 expression is tightly regulated and responds dynamically to neuronal activity, allowing astrocytes to clear approximately ninety percent of synaptic glutamate within a few milliseconds of release[45]. Once internalized, glutamate is converted to glutamine by glutamine synthetase, which is then exported back to neurons where it is reconverted to glutamate by phosphate-activated glutaminase. This cycling process is essential for maintaining neuronal viability and supporting synaptic transmission[45].\n\nThe GABAergic system, operating in parallel, involves SLC1A1 homologs and GABA receptors including GABBR2 and GABRB1. While GABAergic signaling is primarily associated with inhibitory neurotransmission in neurons, astrocytes also express GABA receptors and participate in GABAergic signaling[3][40]. The ionotropic GABA receptors mediate fast, direct effects on cellular membrane potential, while metabotropic GABA receptors like GABBR2 modulate intracellular signaling cascades through G protein coupling[3]. Potassium channels including KCNQ5 (a voltage-gated potassium channel) and KCNN3 (a calcium-activated potassium channel) are crucial for modulating astrocyte excitability and regulating local potassium concentrations in the extracellular space[3]. The removal of excess extracellular potassium released during intense neuronal activity is a critical function of astrocytes, preventing neuronal hyperexcitability and seizures[3].\n\n### Dysregulation in Astrocytoma\n\nThe dysregulation of glutamate homeostasis has been documented as a hallmark feature of gliomas, including astrocytomas. Tumor cells themselves often exhibit reduced glutamate transporter expression, creating a permissive environment for extracellular glutamate accumulation[47]. This accumulation drives excitatory signaling through NMDA receptors and AMPA receptors on both tumor cells and peritumoral neurons, promoting tumor cell migration and proliferation while simultaneously sensitizing peritumoral neurons to excitatory drive[3]. The tumor-associated seizures (TAS) represent a clinical manifestation of this dysregulation; analysis of peritumoral cortex from TAS patients reveals specific transcriptional alterations in peritumoral neurons involving genes implicated in synaptic transmission and synaptic plasticity[3]. The reduced capacity of the peritumoral environment to clear glutamate, combined with altered astrocytic and neuronal glutamate transporter expression, shifts the balance toward excitotoxicity[3][47].\n\n### Significance in Tumor Microenvironment\n\nThe altered glutamate signaling in astrocytoma serves dual roles: it drives tumor cell proliferation through direct receptor signaling while simultaneously creating a hyperexcitable peritumoral environment that favors tumor-adjacent seizures and likely contributes to peritumoral invasion. Multiple genes from the input list directly mediate this process, and the presence of near-complete pathway components suggests robust dysregulation across the glutamate signaling axis. The glutamate transporter genes SLC1A3 and SLC1A4 are central nodes; their dysregulation would impair glutamate clearance capacity. GABAergic signaling components GABBR2 and GABRB1 represent attempts at compensatory inhibition, though this inhibitory capacity is often overwhelmed by the glutamate-driven excitatory drive[3]. Ion channel genes KCNQ5 and KCNN3 participate in the ionic buffering that normally stabilizes the extracellular environment; their dysregulation would contribute to accumulation of extracellular potassium and further neuronal hyperexcitability.\n\n## Gene Program 2: Aquaporin-Mediated Water Transport and Cerebral Edema\n\n### Physiological Water Transport and Astrocyte Function\n\nAquaporins represent a family of water channel proteins whose expression in astrocytes is among the highest of any cell type in the body. Aquaporin-4 (AQP4) is the predominant aquaporin in astrocyte end-feet that contact blood vessels and form the perivascular space[6][9]. The localization of AQP4 to astrocyte end-feet is functionally critical: it enables rapid water influx from blood and cerebrospinal fluid into the brain parenchyma during states of neuronal activity or injury, and facilitates water efflux from the brain when intracranial pressure rises[6][9]. This dynamic water transport capacity is essential for maintaining appropriate brain osmolarity, regulating extracellular space volume, and preventing the pathological accumulation of fluid that characterizes edema[6][9]. The related aquaporin-1 (AQP1) is expressed in meningeal cells and choroid plexus epithelium and contributes to cerebrospinal fluid production and dynamics[11]. Both aquaporins are regulated by osmotic gradients and can be modulated by downstream signaling from G-protein-coupled receptors and ion channels.\n\n### Dysregulation in Glioma and Tumor-Associated Edema\n\nIn glioblastoma and astrocytomas, AQP4 expression is frequently dysregulated. The increased vascular permeability characteristic of high-grade gliomas creates an abnormal osmotic gradient favoring water influx into the tumor mass[6][9][26]. Overexpression or dysregulated AQP4 in tumor-associated astrocytes and tumor cells themselves can amplify water accumulation, contributing to severe peritumoral edema that represents a major source of morbidity and mortality in brain tumor patients[6][9]. Conversely, focal AQP4 loss in regions of tumor infiltration can disrupt the normal osmotic buffering capacity, allowing pathological swelling in specific locations[6][9]. The dual role of AQP4—supporting normal brain physiology while potentially exacerbating tumor-associated edema—makes it a critical node in understanding tumor microenvironment dynamics. Recent evidence suggests that aquaporin overexpression can lead to abnormal water transport and edema formation in meningiomas, and similar mechanisms likely apply to astrocytomas[6][9].\n\n### Functional Implications\n\nThe presence of both AQP4 and AQP1 in the input gene list suggests that water transport dysregulation is a significant feature in this astrocytoma gene program. These genes are required for both the normal functioning of the perivascular astrocyte interface and for the pathological fluid accumulation that characterizes tumor-associated edema. The strategic positioning of these genes at the interface between vascular and parenchymal compartments makes them potential targets for therapeutic intervention to reduce edema while preserving normal water transport capacity during the acute phase of tumor treatment.\n\n## Gene Program 3: Ion Channel and Transporter Networks Mediating Cellular Homeostasis\n\n### Sodium, Potassium, and Calcium Transport Systems\n\nThe maintenance of precise intracellular and extracellular ion concentrations represents a fundamental requirement for cellular excitability and metabolic function. The sodium-potassium ATPase ATP1A2 actively extrudes three sodium ions in exchange for two potassium ions, consuming approximately twenty to forty percent of neuronal ATP and similar proportions in astrocytes[35][45]. This primary active transport mechanism establishes the electrochemical gradients that drive secondary active transport and passive ion fluxes through channels. Beyond ATP1A2, the input gene list includes numerous ion-selective transporters: SLC4A4 (sodium-bicarbonate cotransporter, involved in pH regulation), SLC39A11 (zinc transporter), SLC24A4 (sodium-calcium exchanger for potassium regulation), and SLC14A1 (urea transporter)[35]. The calcium homeostasis mechanisms are particularly critical in astrocytes, which undergo calcium-dependent processes including synaptic transmission modulation, metabolism regulation, and gene expression changes[17][45].\n\nThe inositol-1,4,5-trisphosphate receptor ITPR2, prominently featured in the input list, mediates calcium release from the endoplasmic reticulum in response to phospholipase C activation downstream of G-protein-coupled receptors and phosphoinositide signaling[17]. During oncogenic stress and senescence, increased ITPR2-mediated calcium release combined with mitochondrial calcium uptake via the mitochondrial calcium uniporter causes calcium accumulation in mitochondria, reducing the mitochondrial membrane potential and elevating reactive oxygen species production[17]. This calcium dysregulation represents a central mechanism linking metabolic dysfunction to cellular senescence and is particularly relevant to aging-associated increased glioma susceptibility[17].\n\n### Metabolite and Nutrient Transporters\n\nBeyond simple ion transport, astrocytes express numerous transporters for essential metabolites. The solute carrier family represents the second-largest family of membrane proteins in the human genome, with over 450 members distributed across sixty-five subfamilies[35][37]. Several genes from the input list encode solute carriers with specific metabolic roles: SLC1A3 and SLC1A4 (glutamate), SLC15A2 (peptide transporter), and SLCO1C1 and SLCO3A1 (organic anion transporters)[35][37]. The SLC45A4 gene, encoding a peroxisomal putrescine transporter, represents an emerging example of how metabolite transport dysregulation can affect cellular physiology[37]. Putrescine, a polyamine, is essential for cell proliferation and is frequently elevated in cancer cells, making SLC45A4-mediated putrescine import a potentially important mechanism supporting tumor cell growth[37].\n\n### Dysfunction in Tumor Microenvironment\n\nIn the context of astrocytoma, dysregulation of these ion and metabolite transporters creates a permissive microenvironment for tumor growth while simultaneously compromising normal astrocytic support functions. Altered sodium-potassium ATPase activity, potentially driven by increased neuronal activity in the peritumoral cortex or by direct tumor-released mediators, would shift energy metabolism away from biosynthetic processes toward ion gradient maintenance[35][45]. Dysregulated calcium signaling through ITPR2 and related pathways could promote either astrocyte proliferation (if activated in tumor-associated astrocytes) or astrocyte dysfunction (if dysregulated in normal peritumoral astrocytes)[17]. The cumulative effect of multiple transporter dysregulation would be a fundamental disturbance in cellular ion and metabolite homeostasis, predisposing to pathological excitability, metabolic stress, and ultimately tumor growth acceleration.\n\n## Gene Program 4: Cell Adhesion, Polarity, and Tight Junction Organization\n\n### Structural Basis of Astrocyte Architecture and Blood-Brain Barrier Function\n\nAstrocytes establish a complex three-dimensional architecture through multiple cell adhesion systems. The adherens junction system, anchored by CDH20 (a neural-specific cadherin), maintains physical contacts between astrocytes and between astrocytes and other cell types[40][43][45]. The tight junction proteins, including claudins and occludin partners, work in conjunction with zonula occludens proteins like TJP2 to establish the structural basis of the blood-brain barrier[43]. The Par polarity complex proteins, including PARD3B, organize the spatial distribution of membrane domains and regulate the asymmetric localization of cell adhesion molecules[40][43]. These polarity proteins are critical for establishing and maintaining the distinct molecular and functional properties of astrocyte end-feet that contact blood vessels versus the lateral membrane domains that contact other astrocytes and neurons[43][45].\n\nIntegrin-mediated adhesion to extracellular matrix components, particularly through ITGA6 (integrin α6), provides mechanical stability and contributes to astrocyte positioning within the tissue architecture[34][36]. The spectrin-repeat proteins including UTRN (utrophin) anchor these adhesion molecules to the cytoskeleton, providing mechanical linkage between external matrix contacts and internal cytoskeletal dynamics[43]. The maintenance of proper astrocyte positioning and polarity is not merely a passive structural feature but actively regulates metabolic processes, gene expression, and responsiveness to external signals[43][44].\n\n### Adherence Junction and Barrier Function Dysregulation in Tumors\n\nAstrocytomas, particularly high-grade gliomas, are characterized by profound disruption of the blood-brain barrier, with loss of tight junction integrity, increased vascular permeability, and tumor cell invasion into perivascular spaces[26][46]. This barrier disruption is mediated in part by direct tumor cell secretion of matrix metalloproteinases and vascular permeability factors, but also by dysregulation of the astrocytic adhesion machinery[26][46]. The peritumoral astrocytes transition from a resting state with well-organized end-feet contacts to a reactive state where polarity is lost and end-foot contacts are disrupted[26][43][44]. Recent work demonstrates that plexin-B1 deficiency in astrocytes results in loss of proper astrocyte alignment and aggregation of astrocytes into aberrant clusters, with consequent barrier dysfunction and impaired ability to guide axon growth[43]. This observation suggests that neuron-glial interaction molecules, particularly cell contact-mediated signaling, are essential for maintaining proper astrocyte architecture.\n\nThe input gene list includes the key structural proteins required for barrier integrity: CDH20, PARD3B, TJP2, ITGA6, and UTRN all directly participate in establishing and maintaining the organized astrocytic architecture required for barrier function. The loss or dysregulation of these genes would predictably lead to astrocyte disorganization, barrier dysfunction, and enhancement of tumor cell invasion capacity. The presence of CDHR3, a cadherin-related protein, suggests involvement of additional adhesion pathways that may be dysregulated in tumor contexts.\n\n## Gene Program 5: Cytoskeletal Dynamics and Cell Migration\n\n### Rho GTPase Signaling and Actin Cytoskeleton Organization\n\nThe Rho family of small GTPases—including RhoA, RhoB, Rac, and Cdc42—represent master regulators of cytoskeletal organization and cell motility. These GTPases cycle between active GTP-bound and inactive GDP-bound states through the action of guanine nucleotide exchange factors (GEFs) that promote GTP loading and GTPase-activating proteins (GAPs) that promote GTP hydrolysis. The input gene list includes multiple effectors and regulators of Rho signaling: ARKGEF4 (an exchange factor for Rac), ARHGAP26 (a GTPase-activating protein for Rho family members), and RHOB (RhoB GTPase itself)[26][40][43][44]. Downstream of Rho activation, formin proteins including FMN2 promote unbranched actin polymerization, establishing actin filament networks that drive cell protrusion and migration[40]. The SHROOM3 protein, also in the input list, promotes formation of contractile actin-myosin bundles that generate cellular tension and drive morphological changes[40][43].\n\nThe ankyrin repeat family proteins, particularly ANK2 (ankyrin-2), provide structural scaffolding that links the actin cytoskeleton to membrane proteins, thereby transducing mechanical forces between the external environment and internal signaling cascades[43]. The dystrophin-associated protein DTNA participates in mechanotransduction at specialized membrane domains. Together, these cytoskeletal proteins establish a dynamic system where external stimuli—including cell-cell contacts, growth factor signaling, and mechanical tension—are transduced into changes in cell shape, polarity, and migratory capacity.\n\n### Regulation of Cell Migration and Invasion in Astrocytoma\n\nThe dysregulation of cytoskeletal dynamics is central to tumor cell invasion and migration in astrocytomas[26][40][43]. High-grade gliomas acquire mutations and alterations that enhance Rho GTPase signaling, promoting actin-based protrusions at the leading edge of migrating cells and facilitating invasion through the extracellular matrix[26]. The peritumoral astrocytes themselves undergo reactive transformation characterized by process extension and morphological changes mediated through similar Rho-dependent mechanisms[44][45]. Paradoxically, while peritumoral astrocytes may extend processes that physically contact tumor cells and neurons, this reactive morphology often compromises their barrier-supporting functions[26][43][44]. The specific positioning of the input genes—including both positive regulators like ARKGEF4 and FMN2, and negative regulators like ARHGAP26—suggests that the balance between migration-promoting and migration-inhibiting signals is critically dysregulated in astrocytomas.\n\nRecent evidence indicates that the loss of plexin-B1, a repulsive guidance receptor, in astrocytes leads to impaired astrocyte alignment during spinal cord injury, with astrocytes aggregating into clusters rather than maintaining their normal aligned positioning[43]. This observation has direct relevance to astrocytoma, where peritumoral astrocytes lose their normal organization and may contribute to tumor cell dissemination rather than containment. The convergence of multiple genes from the input list on Rho GTPase and actin dynamics suggests that this program represents a dominant dysregulation pattern in tumor-associated astrocytes.\n\n## Gene Program 6: Receptor Tyrosine Kinase Signaling and Growth Factor Response\n\n### Genetic Drivers in Astrocytoma and RTK Pathway Architecture\n\nAmong the most well-established genetic alterations in astrocytomas are mutations affecting receptor tyrosine kinases (RTKs) and their downstream signaling cascades. Pediatric high-grade gliomas frequently harbor mutations and amplifications in PDGFRA, a receptor for platelet-derived growth factors[1][27][38]. Adult glioblastomas similarly exhibit EGFR amplification and mutations in approximately forty to fifty percent of cases[27]. Recent characterization of pediatric high-grade gliomas has identified fusion genes involving NTRK2, a neurotrophic tyrosine receptor kinase, as recurrent driver alterations[2][27][41]. The TRIM24::NTRK2 fusion identified in a pediatric high-grade glioma case demonstrated robust oncogenic capacity, with both fusion isoforms showing increased cellular proliferation and activation of downstream signaling pathways including MAPK/ERK, PI3K/AKT/mTOR, and JAK/STAT[2][27][41].\n\nThe NTRK2 gene is prominently represented in the input list, and its inclusion underscores the critical role of this receptor in tumor biology. NTRK2 normally functions as a receptor for brain-derived neurotrophic factor (BDNF) and neurotrophin-4, which are essential for neuronal survival, synapse formation, and plasticity in the developing and adult brain[15]. The fusion-mediated constitutive activation of NTRK2 uncouples it from its normal ligand requirement, driving cell survival and proliferation signals even in the absence of BDNF stimulation[2][27][41].\n\n### Signaling Cascade Activation and Convergence\n\nDownstream of NTRK2 and other RTKs lie the MAPK/ERK and PI3K/AKT/mTOR signaling cascades, represented in the input gene list by MAP3K5 (a MAPK kinase kinase) and MAPK4. The dysregulation of these cascades is a hallmark of high-grade gliomas and represents a near-universal consequence of either direct RTK mutations or alterations in negative regulators like NF1 and PTEN[1][27][41]. The input list also includes genes involved in the JAK/STAT pathway, which represents an alternative route to cell survival and proliferation signals downstream of RTKs[27][41]. Notably, recent analyses of pediatric high-grade gliomas following NTRK2 knockout demonstrate that tumors can rapidly activate alternative oncogenic drivers including FLT1, c-KIT, VEGFR2, and other receptor tyrosine kinases, suggesting substantial pathway plasticity and resistance to single-target therapy[2][27][41].\n\n### Implications for Tumor Evolution and Therapeutic Resistance\n\nThe presence of NTRK2 in the input gene list, combined with genes involved in immediate downstream signaling (MAP3K5, MAPK4) and growth factor production (NRG3), indicates that growth factor signaling dysregulation is a central feature. The clinical observation that tumor cells rapidly activate alternative drivers upon knockout of a primary driver suggests that the input gene list may capture multiple potential redundant pathways, each capable of supporting tumor growth. This redundancy has significant implications for therapeutic strategy: targeting a single RTK or downstream effector may select for tumors utilizing alternative pathways represented elsewhere in this gene program.\n\n## Gene Program 7: Lipid Metabolism and Membrane Composition\n\n### Fatty Acid Synthesis and Membrane Remodeling\n\nAstrocytes, unlike most neurons, maintain substantial capacity for de novo lipid synthesis and are important suppliers of lipids and cholesterol to neurons, particularly during periods of active synapse formation and remodeling[45]. The fatty acid desaturase FADS2, present in the input list, catalyzes the insertion of double bonds into fatty acids, generating polyunsaturated fatty acids that are critical components of cell membranes, signaling lipids, and inflammatory mediators[35][45]. The oxysterol-binding protein-related proteins OSBPL11 and OSBPL3 regulate the trafficking and localization of lipids, particularly cholesterol and its derivatives, to specific cellular compartments where they modulate membrane properties and serve as signaling molecules[26][35]. The lipoprotein lipase LPL is involved in the hydrolysis of triglycerides in circulating lipoproteins, making fatty acids available for cellular uptake and utilization[26].\n\n### Altered Lipid Metabolism in Tumor-Associated Astrocytes\n\nRecent investigations of glioma stromal microenvironment have revealed that pericyte-mediated remodeling of the tumor vasculature creates distinct metabolic niches[26]. Within these niches, the balance of lipid synthesis, uptake, and utilization shifts to support tumor cell growth and invasion[26][46]. Astrocytes within the tumor microenvironment may alter their lipid metabolism to provide essential lipids and cholesterol to rapidly proliferating tumor cells, or conversely, may accumulate lipid droplets as a consequence of metabolic dysregulation[26][45][46]. The altered expression of lipid metabolism genes including FADS2, OSBPL11, and OSBPL3 would predictably reshape the membrane composition of tumor-associated astrocytes, potentially affecting their ability to form appropriate contacts with neurons and other cells in the microenvironment[26][35][45][46].\n\n## Gene Program 8: Metabolic Function and Mitochondrial Biology\n\n### Astrocytic Metabolic Support to Neurons and Lactate Shuttle\n\nUnder normal physiological conditions, astrocytes preferentially utilize aerobic glycolysis, converting glucose to lactate even in the presence of adequate oxygen, a phenomenon known as the Warburg effect when observed in tumors[45]. This lactate is exported via monocarboxylate transporters and serves as a preferred oxidative fuel for neurons, which primarily rely on oxidative phosphorylation for ATP production[45]. The glutamate-glutamine cycle, operating in tandem with lactate shuttle, represents a critical metabolic coupling between neurons and astrocytes: glutamate removal by astrocytes is energetically expensive, consuming substantial ATP through the SLC1A3 transporter and glutamine synthetase, yet this cost is partially offset by the simultaneous uptake of glutamine synthetase and subsequent export of glutamine back to neurons[45]. Within the tumor microenvironment, this metabolic cooperation may be disrupted, with tumor cells potentially competing with neurons for astrocytic lactate supply or diverting astrocytic metabolic output toward tumor support[26][45][46].\n\n### Mitochondrial Dysfunction and Senescence\n\nThe tumor protein translationally controlled 1 (TPT1) gene, though not explicitly listed, is related to metabolic control, and many metabolic genes in the input list participate in mitochondrial function. The calcium-dependent processes mediated through ITPR2 and related mechanisms can lead to mitochondrial calcium overload, collapse of the mitochondrial membrane potential, and elevated reactive oxygen species production[17]. This mitochondrial dysfunction is increasingly recognized as a driver of cellular senescence, a state characterized by proliferative arrest coupled with altered gene expression and secretion of pro-inflammatory and pro-tumorigenic factors[17]. In aging brains, cellular senescence may predispose to glioma development through creation of a pro-tumorigenic microenvironment[17].\n\n## Gene Program 9: Reactive Astrocyte Phenotype and Inflammatory Signaling\n\n### Markers and Drivers of Reactive Astrocyte Transformation\n\nReactive astrocytes represent a distinct state characterized by upregulation of glial fibrillary acidic protein (GFAP), altered morphology, and changes in metabolic and signaling properties[44][45]. The sustained upregulation of GFAP in astrocytes adjacent to tumors reflects prolonged exposure to cytokines, growth factors, and metabolic stresses emanating from the tumor[44][45]. Beyond GFAP expression, reactive astrocytes upregulate numerous immune-associated genes, including those involved in complement-mediated synapse pruning (C1qa, Mertk) and toll-like receptor signaling[44]. The toll-like receptor TLR4, present in the input list, is activated by danger-associated molecular patterns including lipopolysaccharides and damage-associated molecular patterns released during tumor progression, necrosis, and immune activation[13][16][44][46]. TLR4 signaling through MyD88 and TRIF leads to activation of NF-κB and MAPK pathways, driving production of pro-inflammatory cytokines including TNF, IL-1β, and IL-6[13][16][44].\n\n### Duration and Evolution of Reactive Astrocyte Response\n\nRecent longitudinal investigations of traumatic brain injury reveal that astrocyte activation is not a transient phenomenon but rather evolves over extended periods[44]. At acute timepoints, the astrocytic transcriptome is dominated by pro-inflammatory gene expression including upregulation of IL-1, IL-6, TNF, and IFN-γ[44]. At subacute timepoints (approximately two weeks), the astrocytic transcriptome begins to shift away from acute inflammation toward signatures associated with neurodegeneration, including upregulation of genes mediating synaptic pruning such as Sparc, Mertk, and C1q components[44]. By chronic timepoints (extending to one year post-injury), the astrocytic transcriptome reflects a mixed phenotype with evidence of both neurodegenerative pathways and pathways involved in tissue remodeling and repair[44]. This temporal evolution suggests that reactive astrocytes in chronic conditions such as astrocytomas would exhibit complex transcriptional signatures reflecting both inflammatory and degenerative processes, rather than a simple binary switch between resting and activated states.\n\n### Immune Checkpoint and Alternative Activation\n\nThe CD38 gene, encoding a cell surface glycoprotein with NADase and ADP-ribosyl transferase activity, plays complex roles in immune regulation[44]. CD38 expression on immune cells is involved in processes including T cell activation and exhaustion, suggesting that its dysregulation in the astrocytoma microenvironment could modulate immune infiltration and efficacy[44]. Emerging evidence indicates that alternative activation states, characterized by distinct transcriptional programs from the classically activated pro-inflammatory state, may predominate in chronic tumor microenvironments[26]. The gene list's inclusion of multiple immune-associated genes suggests that the balance between pro-inflammatory and alternatively activated astrocyte states is dysregulated in astrocytoma.\n\n## Gene Program 10: Neuron-Glial Interaction and Synaptic Plasticity Genes\n\n### Cell-Cell Communication and Adhesion Molecules\n\nThe synaptic adhesion molecules represented in the input list, including TENM4, CNTN1, and NRCAM-related genes, mediate the formation and stabilization of synaptic contacts between neurons and other neurons, between neurons and glia, and potentially between neurons and tumor cells[3][40][45]. TENM4 (teneurin-4) is an axonal adhesion molecule involved in synapse specification and is regulated by neuronal activity and neuromodulatory signals[40][45]. CNTN1 (contactin-1) is a cell adhesion molecule of the immunoglobulin superfamily that mediates heterophilic interactions between neurons and glial cells and is involved in myelination, synaptic transmission, and axonal guidance[40][45]. These adhesion molecules are not merely static structural components but actively participate in bidirectional signaling between neurons and glia, regulating synaptic efficacy, plasticity, and survival.\n\n### Neuron-Derived Growth Factors and Trophic Support\n\nThe neuron-derived growth factor brain-derived neurotrophic factor (BDNF) signals through NTRK2 (TrkB) to support neuronal survival, synaptic transmission, and long-term potentiation[15][40][45]. However, within the tumor microenvironment, the sources and targets of BDNF signaling become complex: tumor cells themselves may produce BDNF or receive BDNF from peritumoral neurons, and peritumoral astrocytes may participate in BDNF sequestration or transport[3][40][45]. The neuregulin NRG3, present in the input list, similarly serves as a glial-derived growth factor that activates ErbB receptors on neurons and plays critical roles in oligodendrocyte development, myelination, and synaptic function[12][40]. The leukemia inhibitory factor receptor LIFR transduces signals from leukemia inhibitory factor (LIF), a pleiotropic cytokine that promotes astrocyte differentiation and activation[40][45]. The dysregulation of these trophic signaling systems in the astrocytoma microenvironment could simultaneously support tumor cell survival while compromising normal neuronal functions.\n\n### Tumor-Associated Seizures and Neuron-Tumor Crosstalk\n\nThe prominence of neuron-glial interaction genes in the input list reflects mounting evidence that direct physical and chemical crosstalk between neurons and tumor cells fundamentally drives tumor progression and generates pathological consequences including seizures[3]. Peritumoral neurons form direct synaptic contacts with tumor cells in vitro and in vivo, with the tumor cells receiving direct excitatory input and releasing neurotransmitters that feed back onto neurons[3]. This bidirectional signaling creates a positive feedback loop where neuronal activity drives tumor cell proliferation and migration, while tumor-released metabolites and growth factors sensitize peritumoral neurons to further firing[3]. The transcriptional alterations observed in peritumoral neurons from TAS patients include upregulation of genes involved in synaptic transmission and plasticity, suggesting that seizure susceptibility reflects both enhanced neuronal excitability and altered intrinsic neuronal properties that promote burst firing[3].\n\n---\n\n## Comprehensive JSON Output\n\n```json\n{\n  \"$schema\": \"http://json-schema.org/draft-07/schema#\",\n  \"context\": {\n    \"cell_type\": \"Astrocyte\",\n    \"disease\": \"Astrocytoma\",\n    \"tissue\": \"Brain\"\n  },\n  \"input_genes\": [\n    \"FAM189A2\", \"OGFRL1\", \"MAP3K5\", \"ITPR2\", \"ETNPPL\", \"NRG3\", \"CD38\", \"FMN2\", \"LINC01088\", \"KCNN3\",\n    \"DAAM2\", \"AC002429.2\", \"OBI1-AS1\", \"NTRK2\", \"SYTL4\", \"WDR49\", \"ADGRV1\", \"LIFR\", \"AQP4\", \"ID3\",\n    \"OSBPL11\", \"DPP10\", \"SERPINI2\", \"TLR4\", \"NAA11\", \"MGAT4C\", \"AC026316.5\", \"EEPD1\", \"RASSF4\", \"AL392086.3\",\n    \"SLC4A4\", \"EDNRB\", \"SLC39A11\", \"ATP1A2\", \"SLCO1C1\", \"AHCYL2\", \"SPON1\", \"SLC1A3\", \"GRAMD2B\", \"DTNA\",\n    \"AC012405.1\", \"NKAIN3\", \"NTM\", \"SLC14A1\", \"DCLK2\", \"DCLK1\", \"ID4\", \"AC124854.1\", \"LINC01094\", \"PCDH9\",\n    \"GABBR2\", \"PARD3B\", \"PDE8A\", \"LRIG1\", \"C5ORF64\", \"RNF19A\", \"SPARCL1\", \"AC093535.1\", \"FADS2\", \"PLEKHA5\",\n    \"ASTN2\", \"ADAMTS9\", \"AC073941.1\", \"SLC24A4\", \"PAPPA\", \"AC068587.4\", \"FARP1\", \"SORL1\", \"ARHGAP26\", \"CADPS\",\n    \"ST3GAL6\", \"ITPKB\", \"GABRB1\", \"FAM107A\", \"MIR99AHG\", \"ANK2\", \"AC107223.1\", \"PPP2R2B\", \"LPL\", \"AL589935.1\",\n    \"MRVI1\", \"TNIK\", \"AL160272.1\", \"AC016766.1\", \"RANBP3L\", \"ARHGEF4\", \"ADCY2\", \"NPL\", \"KCNQ5\", \"AC079352.1\",\n    \"LIX1\", \"APOE\", \"SLC25A48\", \"ADCYAP1R1\", \"AHCYL1\", \"RASL12\", \"GINS3\", \"PTPRG\", \"AL096709.1\", \"BMP2K\",\n    \"MCF2L2\", \"RBMS3\", \"SLCO3A1\", \"AL445426.1\", \"CARMIL1\", \"CACNA2D3\", \"CDHR3\", \"NAV3\", \"UTRN\", \"NRP2\",\n    \"DNAH7\", \"KIAA1671\", \"HPSE2\", \"COL4A5\", \"AC083864.5\", \"L3MBTL4\", \"AC092131.1\", \"PCSK6\", \"AC097450.1\", \"ANOS1\",\n    \"SYNPO2\", \"LINC00836\", \"MAPK4\", \"AL365259.1\", \"WNK2\", \"LMO3\", \"SSBP2\", \"SLC1A4\", \"PPP2R5A\", \"LINC00299\",\n    \"SLC15A2\", \"CNTN1\", \"FKBP5\", \"GREB1L\", \"LUZP2\", \"MAP7\", \"AC023095.1\", \"IGFBP7\", \"ALDH1A1\", \"GRAMD1C\",\n    \"RHBDL3\", \"DAPK1\", \"LINC02058\", \"TENM4\", \"RTN1\", \"LINC01138\", \"GLUD1\", \"NEBL\", \"LINC01117\", \"AC092691.1\",\n    \"TJP2\", \"PCDH9-AS2\", \"YAP1\", \"ABCC9\", \"LAMA1\", \"AL137024.1\", \"ERBB4\", \"ADRA1A\", \"MYBPC1\", \"NT5DC3\",\n    \"AQP1\", \"NKAIN4\", \"ARAP2\", \"RHOB\", \"AQP4-AS1\", \"CDH20\", \"RGMA\", \"OSGIN2\", \"PRKG1\", \"MROH7\",\n    \"PRRX1\", \"MAST4\", \"CHL1\", \"PAPLN\", \"OSBPL3\", \"RFX4\", \"CD44\", \"ATP13A4\", \"COL5A3\", \"ITGA6\",\n    \"DOCK7\", \"CPE\", \"DPF3\", \"ZNF521\", \"DHRS3\", \"AC006148.1\", \"LMNTD1\", \"AC092924.2\", \"LHFPL6\", \"AC024145.1\",\n    \"LIMCH1\", \"SRPX2\", \"AL590999.1\", \"ADCY8\", \"AC008957.2\", \"TTYH2\", \"GJA1\", \"SHROOM3\", \"USH1C\", \"AC007262.2\"\n  ],\n  \"programs\": [\n    {\n      \"program_name\": \"Glutamate Signaling and Neurotransmitter Homeostasis\",\n      \"description\": \"This program encompasses the molecular machinery for bidirectional glutamate-glutamine cycling between neurons and astrocytes, GABA receptor signaling, and potassium buffering. It includes high-affinity glutamate transporters that clear synaptic glutamate within milliseconds, converting it to glutamine for neuronal reuptake. The program operates to maintain appropriate extracellular neurotransmitter concentrations and prevent excitotoxicity. In astrocytoma, this system is dysregulated, allowing glutamate accumulation that drives tumor cell proliferation and peritumoral neuron hyperexcitability, contributing to tumor-associated seizures.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Glutamate uptake and metabolism\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"Glutamate transporter expression in pediatric brain tumors showing dysregulation of SLC1A3 and related genes\"\n            },\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Astrocytes clear ~90% of synaptic glutamate through SLC1A3, essential for synaptic transmission maintenance\"\n            },\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"Reduced glutamate transporter capacity in peritumoral environment creates permissive conditions for excitotoxicity\"\n            }\n          ],\n          \"genes\": [\"SLC1A3\", \"SLC1A4\"]\n        },\n        {\n          \"name\": \"GABA receptor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"GABAergic inhibitory signaling attempts to compensate for glutamate excitotoxicity in peritumoral cortex\"\n            },\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"Dysregulation of GABA signaling pathways in neurodegenerative contexts involving glial cells\"\n            }\n          ],\n          \"genes\": [\"GABBR2\", \"GABRB1\"]\n        },\n        {\n          \"name\": \"Potassium buffering and ion homeostasis\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"Peritumoral neurons show altered intrinsic properties including changes in hyperpolarization-activated currents and potassium dynamics\"\n            },\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Astrocytes regulate extracellular potassium concentration critical for preventing neuronal hyperexcitability\"\n            }\n          ],\n          \"genes\": [\"KCNQ5\", \"KCNN3\"]\n        }\n      ],\n      \"atomic_cellular_components\": [],\n      \"predicted_cellular_impact\": [\n        \"Impaired glutamate clearance capacity leading to extracellular glutamate accumulation\",\n        \"Increased peritumoral neuron hyperexcitability and seizure susceptibility\",\n        \"Enhanced tumor cell proliferation through direct glutamate receptor signaling\",\n        \"Disrupted glutamate-glutamine cycle reducing astrocytic metabolic support to neurons\",\n        \"Altered GABAergic inhibition insufficient to counteract glutamate-driven excitation\"\n      ],\n      \"evidence_summary\": \"The glutamate signaling program represents one of the most well-established mechanisms by which astrocytoma dysregulates normal neuron-glia interactions. Peritumoral neurons exhibit specific transcriptional alterations in genes involved in synaptic transmission, and this dysregulation correlates with tumor-associated seizures. The presence of both glutamate transporters (SLC1A3, SLC1A4) and GABAergic components (GABBR2, GABRB1) in the input list indicates that both arms of excitatory-inhibitory balance are dysregulated. Multiple studies document that tumor cells create hyperexcitable peritumoral environments through mechanisms including glutamate accumulation, and that peritumoral neurons form direct synaptic contacts with tumor cells that amplify this effect.\",\n      \"significance_score\": 0.95,\n      \"citations\": [\n        {\n          \"source_id\": \"1\",\n          \"notes\": \"Patient-derived tumoroids showing dysregulation of neurotransmitter handling pathways\"\n        },\n        {\n          \"source_id\": \"3\",\n          \"notes\": \"Detailed characterization of aberrant neural activity in peritumoral cortex with direct neuron-tumor synaptic contacts\"\n        },\n        {\n          \"source_id\": \"45\",\n          \"notes\": \"Metabolic imaging showing dysregulation of glutamate-glutamine cycling and astrocytic metabolic support\"\n        }\n      ],\n      \"supporting_genes\": [\"SLC1A3\", \"SLC1A4\", \"GABBR2\", \"GABRB1\", \"KCNQ5\", \"KCNN3\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"GLT1 (SLC1A2)\", \"Glutaminase\", \"NMDAR subunits (GRIN1/2)\", \"AMPAR subunits (GRIA2/3)\", \"Glutamine synthetase\"],\n        \"citations\": [\n          {\n            \"source_id\": \"45\",\n            \"notes\": \"Glutamine synthetase essential for converting glutamate to glutamine in astrocytes\"\n          },\n          {\n            \"source_id\": \"3\",\n            \"notes\": \"NMDA and AMPA receptors on neurons and tumor cells mediating excitatory responses to glutamate\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Aquaporin-Mediated Water Transport and Edema Regulation\",\n      \"description\": \"This program encompasses the water channel proteins that regulate fluid balance in the brain, particularly at the astrocyte end-feet that form perivascular interfaces. Aquaporin-4 is localized to astrocyte end-feet and enables rapid water transport across the blood-brain barrier. Aquaporin-1 is expressed in meningeal cells and choroid plexus epithelium. These water channels are essential for maintaining brain osmolarity during normal neuronal activity and for resolving excess water accumulation during injury. In astrocytomas, dysregulation of aquaporin expression contributes to severe edema formation that increases intracranial pressure and morbidity.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Osmotically-driven water transport\",\n          \"citations\": [\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"AQP4 expression in pediatric brain tumors correlates with edema formation and glioma progression\"\n            },\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"Aquaporin-4 overexpression leads to abnormal water transport and edema formation in meningiomas\"\n            }\n          ],\n          \"genes\": [\"AQP4\", \"AQP1\"]\n        },\n        {\n          \"name\": \"Perivascular interface organization\",\n          \"citations\": [\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"Pericyte deficiency in gliomas remodels the tumor microenvironment with increased vessel dysfunction and dysregulated water dynamics\"\n            }\n          ],\n          \"genes\": [\"AQP4\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Astrocyte end-feet\",\n          \"citations\": [\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"AQP4 concentrated in astrocyte end-feet that contact blood vessels\"\n            },\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"End-foot structure and function altered in gliomas affecting water transport capacity\"\n            }\n          ],\n          \"genes\": [\"AQP4\"]\n        },\n        {\n          \"name\": \"Perivascular space\",\n          \"citations\": [\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"Perivascular space remodeling in gliomas with increased edema formation\"\n            }\n          ],\n          \"genes\": [\"AQP4\", \"AQP1\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced water influx into tumor mass contributing to peritumoral edema\",\n        \"Increased intracranial pressure from fluid accumulation\",\n        \"Impaired perivascular water buffering capacity\",\n        \"Disrupted blood-brain barrier function due to aquaporin dysregulation\",\n        \"Altered osmotic gradients favoring tumor growth and invasion\"\n      ],\n      \"evidence_summary\": \"Aquaporin dysregulation is a documented feature of gliomas with direct clinical implications for edema management. The presence of both AQP4 and AQP1 in the input list, combined with known overexpression patterns in high-grade gliomas, indicates robust dysregulation of water transport capacity. Importantly, aquaporin-mediated edema is distinct from vasogenic edema caused by barrier breakdown, as aquaporins actively transport water even across intact endothelial barriers. This dual mechanism of edema formation—barrier dysfunction plus aquaporin-mediated water influx—makes this program particularly relevant to tumor-associated morbidity.\",\n      \"significance_score\": 0.88,\n      \"citations\": [\n        {\n          \"source_id\": \"6\",\n          \"notes\": \"AQP4 expression patterns in pediatric brain tumors\"\n        },\n        {\n          \"source_id\": \"9\",\n          \"notes\": \"Aquaporin overexpression in meningiomas causing water transport dysregulation\"\n        },\n        {\n          \"source_id\": \"26\",\n          \"notes\": \"Perivascular microenvironment remodeling in gliomas\"\n        }\n      ],\n      \"supporting_genes\": [\"AQP4\", \"AQP1\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"Claudin-1, -5\", \"Occludin\", \"ZO-1 (TJP1)\", \"Aquaporin-9 (AQP9)\"],\n        \"citations\": [\n          {\n            \"source_id\": \"26\",\n            \"notes\": \"Tight junction proteins work in concert with aquaporins to regulate fluid dynamics\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Ion Channel and Transporter Mediated Homeostasis\",\n      \"description\": \"This comprehensive program encompasses the active and passive transport mechanisms that establish and maintain ionic gradients essential for cellular excitability, metabolism, and survival. The sodium-potassium ATPase ATP1A2 actively extrudes sodium ions while importing potassium, consuming substantial cellular ATP. The program includes numerous secondary active transporters utilizing the electrochemical gradients established by ATP1A2 to transport glutamate, calcium, zinc, bicarbonate, and other essential ions and metabolites. Dysregulation of this program in astrocytoma leads to fundamental disturbances in cellular homeostasis, metabolic dysfunction, and altered responsiveness to external signals.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Sodium-potassium gradient maintenance\",\n          \"citations\": [\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"ATP1A2 consumes 20-40% of neuronal and glial ATP in maintaining ion gradients\"\n            },\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"ATP1A2 essential for establishing electrochemical gradients that drive glutamate uptake via SLC1A3\"\n            }\n          ],\n          \"genes\": [\"ATP1A2\"]\n        },\n        {\n          \"name\": \"Intracellular calcium signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"ITPR2-mediated calcium release from endoplasmic reticulum during stress leads to mitochondrial calcium accumulation, ROS production, and senescence\"\n            },\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Astrocytic calcium dynamics regulate metabolic processes, synaptic transmission, and gene expression\"\n            }\n          ],\n          \"genes\": [\"ITPR2\", \"SLC24A4\"]\n        },\n        {\n          \"name\": \"Bicarbonate and pH regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"SLC4A4 sodium-bicarbonate cotransporter involved in pH regulation and acid-base balance\"\n            }\n          ],\n          \"genes\": [\"SLC4A4\"]\n        },\n        {\n          \"name\": \"Zinc homeostasis\",\n          \"citations\": [\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"SLC39A7 facilitates zinc ion uptake playing critical role in zinc homeostasis and signaling\"\n            }\n          ],\n          \"genes\": [\"SLC39A11\"]\n        },\n        {\n          \"name\": \"Metabolite and nutrient transport\",\n          \"citations\": [\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"Solute carrier proteins function as metabolic gatekeepers at plasma membrane\"\n            },\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"SLC proteins regulate transport of essential metabolites including polyamines, glucose metabolites, and signaling lipids\"\n            }\n          ],\n          \"genes\": [\"SLC15A2\", \"SLCO1C1\", \"SLCO3A1\", \"SLC25A48\", \"SLC14A1\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Plasma membrane transporters\",\n          \"citations\": [\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"Solute carrier proteins localized at plasma membrane regulate cellular exchange with extracellular environment\"\n            }\n          ],\n          \"genes\": [\"ATP1A2\", \"SLC1A3\", \"SLC1A4\", \"SLC24A4\", \"SLC39A11\", \"SLC4A4\", \"SLC15A2\", \"SLCO1C1\", \"SLCO3A1\", \"SLC25A48\", \"SLC14A1\"]\n        },\n        {\n          \"name\": \"Endoplasmic reticulum calcium release channels\",\n          \"citations\": [\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"ITPR2 calcium channel in endoplasmic reticulum membrane mediates calcium release to cytosol\"\n            }\n          ],\n          \"genes\": [\"ITPR2\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulated sodium-potassium gradients affecting cellular excitability and metabolic capacity\",\n        \"Impaired glutamate uptake due to reduced electrochemical driving force\",\n        \"Pathological calcium accumulation in mitochondria leading to energy depletion and ROS generation\",\n        \"Disrupted pH regulation compromising enzymatic activity and signaling\",\n        \"Altered trace metal homeostasis affecting enzymatic and signaling function\",\n        \"Metabolic stress from excessive ATP consumption attempting to maintain dysregulated ion gradients\"\n      ],\n      \"evidence_summary\": \"The ion channel and transporter program represents fundamental cellular physiology that is profoundly dysregulated in astrocytoma. The ATP1A2 sodium-potassium ATPase alone accounts for 20-40% of cellular ATP consumption, and dysregulation of this pump would cascade through all dependent processes. The presence of ten or more genes in this program from the input list indicates that multiple independent transporter systems are coordinately dysregulated. The calcium dysregulation pathway through ITPR2 is particularly significant given recent evidence linking calcium signaling dysregulation to cellular senescence, a state that promotes pro-tumorigenic microenvironment changes.\",\n      \"significance_score\": 0.92,\n      \"citations\": [\n        {\n          \"source_id\": \"17\",\n          \"notes\": \"Comprehensive review of mitochondrial dysfunction and calcium signaling in senescence\"\n        },\n        {\n          \"source_id\": \"35\",\n          \"notes\": \"Solute carrier proteins as metabolic gatekeepers regulating cellular homeostasis\"\n        },\n        {\n          \"source_id\": \"45\",\n          \"notes\": \"Metabolic coupling between astrocytes and neurons dependent on ion gradient maintenance\"\n        }\n      ],\n      \"supporting_genes\": [\"ATP1A2\", \"ITPR2\", \"SLC24A4\", \"SLC39A11\", \"SLC4A4\", \"SLC15A2\", \"SLCO1C1\", \"SLCO3A1\", \"SLC25A48\", \"SLC14A1\", \"NKAIN3\", \"NKAIN4\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"PTEN (mitochondrial calcium uniporter regulator)\", \"MCU (mitochondrial calcium uniporter)\", \"ATP citrate lyase\", \"Glutamine synthetase\"],\n        \"citations\": [\n          {\n            \"source_id\": \"17\",\n            \"notes\": \"MCU essential for mitochondrial calcium uptake that triggers senescence pathways\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Cell Adhesion, Polarity, and Tight Junction Organization\",\n      \"description\": \"This program encompasses the molecular machinery establishing cell-cell contacts, maintaining cellular polarity, and forming barrier structures including tight junctions. Key components include neural cadherins (CDH20) mediating adherens junctions between astrocytes and other cell types, zonula occludens proteins (TJP2) anchoring tight junction scaffolds, Par polarity complex proteins (PARD3B) establishing membrane domain organization, integrin adhesion molecules (ITGA6), and cytoskeletal linkers (UTRN, DTNA) connecting adhesion molecules to internal cytoskeletal structures. These systems are essential for establishing astrocyte end-feet architecture, maintaining blood-brain barrier integrity, and enabling proper spatial organization within brain tissue. In astrocytoma, loss of polarity and barrier function accompanies tumor progression and facilitates invasion.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Adherens junction formation and maintenance\",\n          \"citations\": [\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"CDH20 and related cadherins establish adherens junctions between astrocytes and other cell types\"\n            },\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Cell-cell adhesion essential for astrocyte positioning and coordinated metabolic support to neurons\"\n            }\n          ],\n          \"genes\": [\"CDH20\", \"ITGA6\"]\n        },\n        {\n          \"name\": \"Tight junction assembly and barrier function\",\n          \"citations\": [\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"TJP2 anchors tight junction proteins including claudins and occludin to maintain blood-brain barrier\"\n            },\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"Tight junction disruption in gliomas correlates with increased vascular permeability and edema\"\n            }\n          ],\n          \"genes\": [\"TJP2\", \"PARD3B\"]\n        },\n        {\n          \"name\": \"Cellular polarity establishment\",\n          \"citations\": [\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"PARD3B and Par polarity complex proteins establish asymmetric membrane domain organization essential for astrocyte function\"\n            }\n          ],\n          \"genes\": [\"PARD3B\"]\n        },\n        {\n          \"name\": \"Cadherin-adhesion molecule complex organization\",\n          \"citations\": [\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"Cadherins and related adhesion molecules work in coordination to establish cell contact specificity and signaling\"\n            }\n          ],\n          \"genes\": [\"CDHR3\", \"CDH20\", \"PCDH9\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Adherens junctions\",\n          \"citations\": [\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"Adherens junction complexes composed of cadherins, catenins, and cytoskeletal anchors maintain cell-cell contacts\"\n            }\n          ],\n          \"genes\": [\"CDH20\", \"CDHR3\", \"PCDH9\", \"ITGA6\"]\n        },\n        {\n          \"name\": \"Tight junctions\",\n          \"citations\": [\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"Tight junction sealing strands formed by claudins, occludin, and junction adhesion molecules anchored to TJP2 scaffold\"\n            }\n          ],\n          \"genes\": [\"TJP2\", \"PARD3B\"]\n        },\n        {\n          \"name\": \"Astrocyte end-feet\",\n          \"citations\": [\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"Astrocyte end-feet specialized membrane domains that contact blood vessels and establish perivascular space\"\n            },\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"Astrocyte end-feet organization requires coordinated cell polarity and adhesion molecule expression\"\n            }\n          ],\n          \"genes\": [\"CDH20\", \"TJP2\", \"PARD3B\", \"UTRN\", \"DTNA\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Loss of polarity with disruption of specialized membrane domains including astrocyte end-feet\",\n        \"Barrier dysfunction with increased vascular permeability and edema formation\",\n        \"Enhanced tumor cell invasion through perivascular spaces\",\n        \"Impaired astrocyte-neuron spatial organization compromising metabolic support\",\n        \"Disrupted adherens junctions allowing aberrant cell movements\",\n        \"Loss of contact inhibition potentially promoting proliferation\"\n      ],\n      \"evidence_summary\": \"The cell adhesion and polarity program represents a critical layer of barrier organization that is profoundly dysregulated in gliomas. Recent evidence demonstrates that loss of plexin-B1, which regulates astrocyte membrane dynamics, results in loss of proper astrocyte alignment and organization, with astrocytes aggregating into clusters rather than forming the normal organized framework. This observation directly parallels the architectural disruption observed in peritumoral regions of gliomas. The presence of six distinct adhesion and polarity-related genes in the input list—CDH20, TJP2, PARD3B, ITGA6, UTRN, DTNA—indicates that the entire adhesion complex is affected. The loss of barrier function in high-grade gliomas is well-established, and the specific dysregulation of these genes explains the mechanisms by which barrier integrity is compromised.\",\n      \"significance_score\": 0.90,\n      \"citations\": [\n        {\n          \"source_id\": \"26\",\n          \"notes\": \"Comprehensive characterization of perivascular microenvironment remodeling in gliomas\"\n        },\n        {\n          \"source_id\": \"43\",\n          \"notes\": \"Plexin-B1 regulation of astrocyte alignment and polarity establishment\"\n        },\n        {\n          \"source_id\": \"46\",\n          \"notes\": \"Spatial transcriptomic analysis of ECM and stromal cell organization in glioblastoma showing disrupted cell positioning\"\n        }\n      ],\n      \"supporting_genes\": [\"CDH20\", \"TJP2\", \"PARD3B\", \"ITGA6\", \"UTRN\", \"DTNA\", \"CDHR3\", \"PCDH9\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"Claudin-5, -11\", \"Occludin\", \"JAM-A, -C\", \"ZO-2, ZO-3\", \"Catenins (α, β, γ)\", \"Integrins (α3, α5, β1)\"],\n        \"citations\": [\n          {\n            \"source_id\": \"43\",\n            \"notes\": \"Multiple claudins and junction proteins work in coordination to establish functional tight junctions\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Cytoskeletal Dynamics and Cell Migration\",\n      \"description\": \"This program governs the dynamic remodeling of actin and microtubule networks that drive cell morphology changes, migration, and invasion. The program is anchored by Rho family GTPases (RHOB) that cycle between active and inactive states, with guanine nucleotide exchange factors (ARKGEF4) promoting GTP loading and GTPase-activating proteins (ARHGAP26) promoting GTP hydrolysis. Downstream of Rho GTPases, formin proteins (FMN2) promote unbranched actin polymerization, while shroom proteins (SHROOM3) generate contractile actin-myosin bundles. Scaffolding proteins including ANK2 (ankyrin-2) link the dynamic actin cytoskeleton to membrane proteins, enabling mechanotransduction. These systems coordinate cell shape changes necessary for migration, invasion, and interaction with the extracellular matrix.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Rho GTPase signaling and regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"Enhanced Rho signaling in gliomas promotes actin-based protrusions at leading edge of migrating cells\"\n            },\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"Rho GTPases regulate astrocyte morphology and process extension\"\n            },\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"Plexin-B1 regulation of Rho GTPases critical for astrocyte alignment and spatial organization\"\n            }\n          ],\n          \"genes\": [\"RHOB\", \"ARKGEF4\", \"ARHGAP26\"]\n        },\n        {\n          \"name\": \"Actin polymerization and filament assembly\",\n          \"citations\": [\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"Formin proteins drive unbranched actin polymerization generating contractile filament networks\"\n            },\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"Shroom proteins generate contractile actin-myosin bundles driving cellular tension and morphological changes\"\n            }\n          ],\n          \"genes\": [\"FMN2\", \"SHROOM3\", \"DAAM2\"]\n        },\n        {\n          \"name\": \"Cytoskeletal-membrane protein linking\",\n          \"citations\": [\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"Ankyrin proteins link membrane proteins to actin cytoskeleton enabling mechanotransduction\"\n            }\n          ],\n          \"genes\": [\"ANK2\", \"DTNA\", \"UTRN\"]\n        },\n        {\n          \"name\": \"Cell motility and migration\",\n          \"citations\": [\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"Dysregulated Rho signaling in gliomas promotes tumor cell invasion and migration\"\n            },\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"Reactive astrocytes extend processes through Rho-dependent mechanisms in response to injury\"\n            }\n          ],\n          \"genes\": [\"RHOB\", \"ARKGEF4\", \"FMN2\", \"SHROOM3\", \"ANK2\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Actin filament networks\",\n          \"citations\": [\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"Formin-nucleated actin filaments essential for cell protrusions and migration\"\n            }\n          ],\n          \"genes\": [\"FMN2\", \"DAAM2\", \"SHROOM3\"]\n        },\n        {\n          \"name\": \"Spectrin-repeat cytoskeletal network\",\n          \"citations\": [\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"Dystrophin and related spectrin proteins form membrane-associated network providing mechanical stability\"\n            }\n          ],\n          \"genes\": [\"DTNA\", \"UTRN\", \"ANK2\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced cell motility and invasion capacity in tumor-associated astrocytes\",\n        \"Dysregulated astrocyte morphology and loss of normal organized architecture\",\n        \"Increased mechanotransduction of external signals into cytoskeletal rearrangement\",\n        \"Enhanced tumor cell migration and dissemination capacity\",\n        \"Impaired astrocyte-axon alignment and guidance function\",\n        \"Loss of organized astrocyte network required for barrier function\"\n      ],\n      \"evidence_summary\": \"The cytoskeletal dynamics program represents a central mechanism by which astrocytomas dysregulate normal astrocyte function while simultaneously enabling tumor cell invasion and migration. Recent evidence demonstrates that loss of plexin-B1, a regulator of Rho GTPase signaling, in astrocytes results in disorganization of astrocyte processes and loss of proper alignment required for axon guidance and tissue organization. This observation directly parallels the architectural disorganization observed in peritumoral gliomas. The presence of eight genes in the input list related to Rho signaling, actin polymerization, and cytoskeletal linking indicates that this program is comprehensively dysregulated. The presence of both positive regulators (ARKGEF4, FMN2) and negative regulators (ARHGAP26) suggests that the balance between migration promotion and migration restriction is fundamentally altered.\",\n      \"significance_score\": 0.89,\n      \"citations\": [\n        {\n          \"source_id\": \"26\",\n          \"notes\": \"Dysregulated Rho signaling in pericyte-depleted gliomas promoting tumor cell invasion\"\n        },\n        {\n          \"source_id\": \"40\",\n          \"notes\": \"Rho-dependent cytoskeletal dynamics in neuronal reprogramming of astrocytes\"\n        },\n        {\n          \"source_id\": \"43\",\n          \"notes\": \"Plexin-B1 regulation of astrocyte polarity and alignment through Rho GTPase modulation\"\n        }\n      ],\n      \"supporting_genes\": [\"RHOB\", \"ARKGEF4\", \"ARHGAP26\", \"FMN2\", \"SHROOM3\", \"DAAM2\", \"ANK2\", \"DTNA\", \"UTRN\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"Rac1/3\", \"Cdc42\", \"Cofilin\", \"Profilin\", \"Arp2/3 complex\", \"Myosin IIA/IIB\", \"Merlin (NF2)\", \"Plexin-B1\"],\n        \"citations\": [\n          {\n            \"source_id\": \"43\",\n            \"notes\": \"Multiple GTPases and actin regulators work in concert to control cytoskeletal dynamics\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Receptor Tyrosine Kinase Signaling and Oncogenic Pathway Activation\",\n      \"description\": \"This program encompasses the dysregulated growth factor receptor signaling that drives oncogenic transformation in astrocytomas. The neurotrophic tyrosine receptor kinase NTRK2 normally transduces signals from neurotrophins BDNF and NT-4 to promote neuronal survival and synapse formation, but is frequently dysregulated through fusion genes (such as TRIM24::NTRK2) or point mutations in high-grade gliomas. Downstream of NTRK2 and other receptor tyrosine kinases including PDGFRA, EGFR, and FLT1, lie the MAPK/ERK and PI3K/AKT/mTOR signaling cascades, represented by MAP3K5 and MAPK4. These cascades converge on JAK/STAT signaling. The program also includes genes involved in growth factor production (NRG3) and receptor modulation (LRIG1). Dysregulation of this program is near-universal in high-grade gliomas and represents a primary driver of unchecked proliferation and survival.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"NTRK2 neurotrophic receptor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"TRIM24::NTRK2 fusion gene identified in pediatric high-grade glioma showing robust oncogenic capacity\"\n            },\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"NTRK2 fusion displays oncogenic capacity with increased cellular proliferation over 72 hours\"\n            },\n            {\n              \"source_id\": \"41\",\n              \"notes\": \"NTRK2 activation of MAPK, PI3K, and JAK/STAT pathways in tumor cells\"\n            }\n          ],\n          \"genes\": [\"NTRK2\"]\n        },\n        {\n          \"name\": \"MAPK/ERK signaling cascade\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"NTRK2 fusion activation shows most prominent activation of MAPK pathway with pERK elevation over time\"\n            },\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"MAP3K5 and downstream MAPK signaling activated in response to growth factor receptor signaling\"\n            }\n          ],\n          \"genes\": [\"MAP3K5\", \"MAPK4\"]\n        },\n        {\n          \"name\": \"PI3K/AKT/mTOR pathway activation\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"High-grade pediatric gliomas show mutations and amplifications in PIK3CA activating PI3K signaling\"\n            },\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"NTRK2 fusion drives 2.9-3.3 fold increase in pAKT and 11-13.8 fold increase in pS6, indicating strong PI3K pathway activation\"\n            }\n          ],\n          \"genes\": [\"NTRK2\"]\n        },\n        {\n          \"name\": \"JAK/STAT pathway activation\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"NTRK2 fusion activates JAK/STAT signaling with prominent pSTAT3 nuclear staining in later operations\"\n            },\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"JAK/STAT pathway activation represents alternative survival and proliferation signaling downstream of RTKs\"\n            }\n          ],\n          \"genes\": [\"NTRK2\"]\n        },\n        {\n          \"name\": \"Growth factor production and paracrine signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"NRG3 and other growth factors produced by glioma cells and stromal cells support tumor growth\"\n            },\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"NRG3 serves as glial-derived growth factor activating ErbB receptors on neurons\"\n            }\n          ],\n          \"genes\": [\"NRG3\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Receptor tyrosine kinase complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"NTRK2 forms active receptor tyrosine kinase complexes when activated by neurotrophic ligands or constitutively when fused\"\n            }\n          ],\n          \"genes\": [\"NTRK2\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Constitutive activation of growth signaling pathways independent of ligand availability\",\n        \"Unchecked proliferation and survival signaling in tumor cells\",\n        \"Resistance to growth factor deprivation through multiple pathway redundancy\",\n        \"Enhanced metabolic activity and energy consumption\",\n        \"Increased secretion of growth factors and cytokines supporting tumor microenvironment\",\n        \"Rapid pathway switching to alternative drivers upon inhibition of primary receptor\",\n        \"Direct trophic support of peritumoral neurons through NRG3 and related factors\"\n      ],\n      \"evidence_summary\": \"The receptor tyrosine kinase signaling program represents one of the most well-established mechanisms of astrocytoma oncogenesis. The presence of NTRK2 in the input list is particularly significant given recent characterization of TRIM24::NTRK2 fusion in pediatric high-grade gliomas, which demonstrates potent activation of multiple downstream pathways. Importantly, studies tracking tumor evolution over multiple surgical resections demonstrate that despite NTRK2 knockout in engineered cells causing marked reduction in downstream signaling, tumors progressively lose reliance on NTRK2 while acquiring alternative oncogenic drivers including other tyrosine kinases (FGFR2, c-KIT, VEGFR2). This observation suggests substantial pathway plasticity and explains why single-target therapy approaches often fail. The presence of NRG3 in the input list indicates that growth factor production, not just reception, is dysregulated in astrocytomas.\",\n      \"significance_score\": 0.94,\n      \"citations\": [\n        {\n          \"source_id\": \"2\",\n          \"notes\": \"Comprehensive characterization of TRIM24::NTRK2 fusion and its oncogenic pathway activation\"\n        },\n        {\n          \"source_id\": \"27\",\n          \"notes\": \"NTRK2 displays robust oncogenic capacity and drives multiple downstream signaling pathways\"\n        },\n        {\n          \"source_id\": \"41\",\n          \"notes\": \"Patient-derived cells show decreased response to TRK inhibitors over time with activation of alternative oncogenic drivers\"\n        }\n      ],\n      \"supporting_genes\": [\"NTRK2\", \"MAP3K5\", \"MAPK4\", \"NRG3\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"PDGFRA\", \"EGFR\", \"FLT1\", \"c-KIT\", \"VEGFR2\", \"PLCγ\", \"SOS\", \"RAF\", \"ERK1/2\", \"AKT1/2\", \"mTOR\", \"STAT3\", \"SHP2\"],\n        \"citations\": [\n          {\n            \"source_id\": \"1\",\n            \"notes\": \"Multiple receptor tyrosine kinases dysregulated in high-grade gliomas\"\n          },\n          {\n            \"source_id\": \"27\",\n              \"notes\": \"Complete pathway components required for full implementation of RTK-driven oncogenic signaling\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Lipid Metabolism and Membrane Composition Regulation\",\n      \"description\": \"This program governs the synthesis, transport, and localization of lipids including fatty acids, cholesterol, and signaling lipids that are essential components of cellular membranes and participate in cell signaling. The fatty acid desaturase FADS2 catalyzes insertion of double bonds into fatty acids, generating polyunsaturated fatty acids that are critical for membrane fluidity, signaling lipid production, and inflammatory mediator synthesis. Oxysterol-binding protein-related proteins (OSBPL11, OSBPL3) regulate cholesterol and oxysterol trafficking and localization. Lipoprotein lipase (LPL) participates in hydrolysis of circulating triglycerides. The balance of lipid synthesis, uptake, and utilization is profoundly altered in gliomas, where tumor-associated astrocytes may accumulate lipid droplets or alter membrane composition to support tumor cell growth.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Polyunsaturated fatty acid synthesis\",\n          \"citations\": [\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"FADS2 catalyzes insertion of double bonds in fatty acids generating polyunsaturated fatty acids\"\n            },\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Astrocytes maintain substantial capacity for de novo lipid synthesis including polyunsaturated fatty acids\"\n            }\n          ],\n          \"genes\": [\"FADS2\"]\n        },\n        {\n          \"name\": \"Cholesterol and oxysterol trafficking\",\n          \"citations\": [\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"Oxysterol-binding proteins regulate lipid trafficking to support tumor cell proliferation and microenvironment remodeling\"\n            },\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"OSBPL proteins regulate subcellular localization of lipids affecting membrane properties and signaling\"\n            }\n          ],\n          \"genes\": [\"OSBPL11\", \"OSBPL3\"]\n        },\n        {\n          \"name\": \"Lipoprotein metabolism\",\n          \"citations\": [\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"Lipoprotein lipase participates in lipid supply dynamics within tumor microenvironment\"\n            }\n          ],\n          \"genes\": [\"LPL\"]\n        },\n        {\n          \"name\": \"Membrane composition remodeling\",\n          \"citations\": [\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Altered membrane lipid composition affects astrocyte morphology, signaling, and cell-cell interactions\"\n            }\n          ],\n          \"genes\": [\"FADS2\", \"OSBPL11\", \"OSBPL3\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Cell membrane lipid bilayer\",\n          \"citations\": [\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"Fatty acids and cholesterol are essential structural components of cell membranes\"\n            }\n          ],\n          \"genes\": [\"FADS2\", \"OSBPL11\", \"OSBPL3\"]\n        },\n        {\n          \"name\": \"Lipid droplets\",\n          \"citations\": [\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"Lipid droplet accumulation observed in metabolically dysfunctional astrocytes in gliomas\"\n            }\n          ],\n          \"genes\": [\"FADS2\", \"OSBPL11\", \"LPL\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Altered membrane fluidity affecting cell-cell signaling and interactions\",\n        \"Dysregulated signaling lipid production affecting intracellular and intercellular signaling\",\n        \"Enhanced or reduced astrocytic lipid provision to neurons based on metabolic state\",\n        \"Altered astrocyte morphology through membrane composition changes\",\n        \"Enhanced tumor cell lipid supply through altered astrocytic lipid metabolism\",\n        \"Dysregulated inflammatory lipid mediator production\"\n      ],\n      \"evidence_summary\": \"The lipid metabolism program represents an emerging area of glioma biology where altered metabolic cooperation between tumor cells and astrocytes affects tumor progression. While specific dysregulation of FADS2 and OSBPL genes has not been extensively characterized in astrocytomas, the general principle that tumor-associated astrocytes undergo metabolic reprogramming is well-established. The presence of three lipid metabolism genes (FADS2, OSBPL11, OSBPL3, LPL) in the input list suggests that this program merits closer investigation. Recent studies of pericyte-depleted gliomas reveal altered metabolic niches within the tumor microenvironment, and lipid metabolism is a key component of this remodeling.\",\n      \"significance_score\": 0.72,\n      \"citations\": [\n        {\n          \"source_id\": \"26\",\n          \"notes\": \"Pericyte-mediated remodeling of tumor metabolic niches including lipid availability\"\n        },\n        {\n          \"source_id\": \"35\",\n          \"notes\": \"Solute carrier and enzymatic control of lipid metabolism\"\n        },\n        {\n          \"source_id\": \"45\",\n          \"notes\": \"Astrocytic lipid synthesis and provision to neurons\"\n        }\n      ],\n      \"supporting_genes\": [\"FADS2\", \"OSBPL11\", \"OSBPL3\", \"LPL\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"SREBP (sterol regulatory element-binding protein)\", \"ChREBP (carbohydrate-responsive transcription factor)\", \"ACC (acetyl-CoA carboxylase)\", \"FASN (fatty acid synthase)\", \"Apolipoprotein E\"],\n        \"citations\": [\n          {\n            \"source_id\": \"26\",\n            \"notes\": \"Transcriptional regulation of lipid synthesis genes critical for metabolic reprogramming\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Metabolic Function and Mitochondrial Homeostasis\",\n      \"description\": \"This program encompasses the molecular systems regulating cellular metabolism and mitochondrial function, including aerobic respiration, glycolytic pathways, and biosynthetic processes. Under normal conditions, astrocytes preferentially utilize aerobic glycolysis while neurons rely primarily on oxidative phosphorylation. The metabolic coupling between astrocytes (providing lactate) and neurons (consuming lactate for oxidative metabolism) represents a critical feature of brain energy metabolism. Within the tumor microenvironment, this metabolic cooperation is disrupted, with tumor cells competing for metabolic substrates and potentially forcing metabolic reprogramming in peritumoral astrocytes. Mitochondrial calcium dysregulation through ITPR2-mediated mechanisms leads to collapse of mitochondrial membrane potential, ROS accumulation, and activation of senescence pathways.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Aerobic metabolism and energy production\",\n          \"citations\": [\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Astrocytes utilize aerobic glycolysis preferentially, producing lactate as major metabolic fuel for neurons\"\n            }\n          ],\n          \"genes\": [\"GLUD1\"]\n        },\n        {\n          \"name\": \"Mitochondrial calcium handling and energetics\",\n          \"citations\": [\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"ITPR2-mediated calcium release to mitochondria during stress leads to mitochondrial dysfunction, ROS production, and senescence\"\n            },\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Astrocyte mitochondrial metabolism differs from neurons with greater flexibility in energy substrate utilization\"\n            }\n          ],\n          \"genes\": [\"ITPR2\"]\n        },\n        {\n          \"name\": \"Oxidative stress response and antioxidant metabolism\",\n          \"citations\": [\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Astrocytes possess robust antioxidant systems including GSH and NADPH pools, supporting neurons more susceptible to ROS\"\n            }\n          ],\n          \"genes\": [\"ALDH1A1\"]\n        },\n        {\n          \"name\": \"Senescence and metabolic dysfunction\",\n          \"citations\": [\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"Mitochondrial calcium overload, ROS accumulation, and impaired mitochondrial quality control drive senescence induction\"\n            }\n          ],\n          \"genes\": [\"ITPR2\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Mitochondrial matrix\",\n          \"citations\": [\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"Calcium accumulation in mitochondrial matrix reduces membrane potential and elevates ROS production\"\n            }\n          ],\n          \"genes\": [\"ITPR2\"]\n        },\n        {\n          \"name\": \"Astrocyte and neuron metabolic coupling interface\",\n          \"citations\": [\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Lactate shuttle and glutamate-glutamine cycle establish metabolic coupling between astrocytes and neurons\"\n            }\n          ],\n          \"genes\": [\"GLUD1\", \"ALDH1A1\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulated astrocytic-neuronal metabolic coupling reducing neuronal energy availability\",\n        \"Increased reactive oxygen species generation from mitochondrial dysfunction\",\n        \"Cellular senescence in chronically stressed peritumoral astrocytes\",\n        \"Altered astrocytic lactate production affecting neuronal oxidative metabolism\",\n        \"Reduced antioxidant capacity in peritumoral astrocytes affecting neuroprotection\",\n        \"Metabolic stress promoting astrocyte activation and inflammatory gene expression\",\n        \"Tumor cells competing for metabolic resources with peritumoral neurons\"\n      ],\n      \"evidence_summary\": \"The metabolic function program is critically dysregulated in astrocytomas, though the specific role of individual genes remains partially understood. The presence of ITPR2 in the input list is particularly significant given recent evidence linking calcium-mediated mitochondrial dysfunction to cellular senescence and pro-tumorigenic microenvironment changes. The aging brain is predisposed to glioma development, and senescence-associated metabolic changes likely contribute to this increased susceptibility. Additionally, recent multi-modal imaging of brain cell metabolism reveals distinct differences between astrocytes, neurons, and microglia, with astrocytes maintaining flexible metabolic capacity that can support tumor growth. The glutamate-metabolizing enzyme GLUD1 participates in astrocytic GABA synthesis through the putrescine pathway, connecting glutamate metabolism to polyamine metabolism essential for cell proliferation.\",\n      \"significance_score\": 0.80,\n      \"citations\": [\n        {\n          \"source_id\": \"17\",\n          \"notes\": \"Comprehensive review of mitochondrial dysfunction in cellular senescence\"\n        },\n        {\n          \"source_id\": \"45\",\n          \"notes\": \"Multi-modal label-free imaging of astrocyte and neuronal metabolism and metabolic interactions\"\n        }\n      ],\n      \"supporting_genes\": [\"ITPR2\", \"GLUD1\", \"ALDH1A1\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"MCT1, MCT4 (monocarboxylate transporters)\", \"GLUL (glutamine synthetase)\", \"GABA synthesis enzymes\", \"SOD (superoxide dismutase)\", \"Catalase\", \"Complex I-IV (electron transport chain)\", \"ATP synthase\"],\n        \"citations\": [\n          {\n            \"source_id\": \"45\",\n            \"notes\": \"Multiple genes required for complete lactate shuttle and antioxidant metabolism\"\n          },\n          {\n            \"source_id\": \"35\",\n            \"notes\": \"MCT1 and MCT4 essential for monocarboxylate transport including lactate\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Reactive Astrocyte Phenotype and Inflammatory Immune Signaling\",\n      \"description\": \"This program governs the transformation of resting astrocytes into reactive astrocytes characterized by upregulation of glial fibrillary acidic protein (GFAP), altered morphology, enhanced cytokine production, and recruitment of immune cells. Reactive astrocytes upregulate toll-like receptor signaling (TLR4), complement-mediated synapse pruning genes (including C1q related genes), and produce pro-inflammatory cytokines (TNF, IL-1β, IL-6, IFN-γ). This reactive transformation is triggered by danger-associated molecular patterns released during tumor necrosis and immune activation, direct tumor-released mediators, and metabolic stress. While acute reactive astrocyte responses may initially contain tumor growth, chronic reactive transformation creates a pro-tumorigenic microenvironment through production of growth factors, cytokines supporting alternative macrophage activation, and reduced neuronal support functions.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Toll-like receptor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"TLR4 activation by danger-associated molecular patterns leads to NF-κB and MAPK pathway activation\"\n            },\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"TLR4 signaling in astrocytes drives inflammatory cytokine production\"\n            },\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"TLR4-mediated inflammatory signaling prominent in acute phase of traumatic brain injury with elevated pro-inflammatory gene expression\"\n            }\n          ],\n          \"genes\": [\"TLR4\"]\n        },\n        {\n          \"name\": \"GFAP expression and reactive astrocyte marker upregulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"GFAP expression used as marker of astrocytic differentiation in patient-derived tumoroids\"\n            },\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"GFAP upregulated across all phases of post-injury response reflecting sustained astrocyte activation\"\n            }\n          ],\n          \"genes\": [\"GFAP\"]\n        },\n        {\n          \"name\": \"Complement-mediated synapse pruning\",\n          \"citations\": [\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"C1qa, Mertk, and related genes upregulated in subacute phase reflecting transition to neurodegenerative processes\"\n            }\n          ],\n          \"genes\": [\"SPARCL1\"]\n        },\n        {\n          \"name\": \"Immune cell recruitment and macrophage polarization\",\n          \"citations\": [\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"Pericyte deficiency in gliomas increases alternatively activated macrophages and MDSCs supporting immune suppression\"\n            },\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"Altered immune cell infiltration and composition in chronic post-injury phase\"\n            }\n          ],\n          \"genes\": [\"TLR4\", \"CD38\"]\n        },\n        {\n          \"name\": \"Pro-inflammatory cytokine production\",\n          \"citations\": [\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"IL-1β, IL-6, TNF, and IFN-γ upregulated in acute phase astrocytes, declining in subacute phase\"\n            }\n          ],\n          \"genes\": [\"TLR4\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Astrocyte morphology and process structure\",\n          \"citations\": [\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"Reactive astrocytes characterized by upregulation of intermediate filament GFAP and extension of elaborate hypertrophic processes\"\n            },\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"Sustained astrocyte activation with morphological changes across acute, subacute, and chronic phases\"\n            }\n          ],\n          \"genes\": [\"GFAP\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced pro-inflammatory cytokine production supporting immune infiltration\",\n        \"Shift toward alternatively activated immune phenotype in chronic states reducing anti-tumor immunity\",\n        \"Enhanced synapse pruning through complement and related mechanisms affecting peritumoral neuronal function\",\n        \"Reduced metabolic support to neurons due to reactive astrocyte redirection of resources toward inflammation\",\n        \"Sustained upregulation of reactive markers even in chronic states\",\n        \"Production of pro-tumorigenic factors including growth factors and chemokines\"\n      ],\n      \"evidence_summary\": \"The reactive astrocyte program is comprehensively dysregulated in astrocytomas, with astrocytes transitioning from resting to reactive states in response to tumor-derived mediators. The temporal evolution of the reactive astrocyte response, from acute pro-inflammatory phase through subacute transition phase to chronic phase with mixed inflammatory and neurodegenerative signatures, suggests that the astrocytic response to chronic tumor presence involves complex temporal dynamics. The presence of TLR4 in the input list is particularly significant, as TLR4-mediated inflammatory signaling represents a major pathway through which danger signals activate astrocytes. The presence of CD38, which modulates immune checkpoint functions, suggests that immune regulation is also dysregulated. Importantly, recent evidence indicates that while acute astrocyte activation may contain tumor growth, chronic activation creates a pro-tumorigenic microenvironment through production of growth factors, reduction of neuronal support functions, and shift of immune cells toward alternative activation states that support tumor growth.\",\n      \"significance_score\": 0.85,\n      \"citations\": [\n        {\n          \"source_id\": \"26\",\n          \"notes\": \"Pericyte-mediated control of immune cell polarization in gliomas\"\n        },\n        {\n          \"source_id\": \"44\",\n          \"notes\": \"Comprehensive temporal analysis of astrocyte transcriptome following traumatic brain injury showing sustained activation and phenotypic evolution\"\n        }\n      ],\n      \"supporting_genes\": [\"TLR4\", \"CD38\", \"SPARCL1\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"IL-1β\", \"IL-6\", \"TNF\", \"IFN-γ\", \"NF-κB\", \"MAPK14\", \"MyD88\", \"TRIF\", \"NLRP3\", \"C1qa\", \"C1qb\", \"C1qc\", \"Mertk\"],\n        \"citations\": [\n          {\n            \"source_id\": \"44\",\n            \"notes\": \"Multiple cytokines and signaling molecules required for full inflammatory response\"\n          },\n          {\n            \"source_id\": \"13\",\n            \"notes\": \"NLRP3 inflammasome assembly and activation required for IL-1β and IL-18 production\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Neuron-Glial Interaction and Synaptic Plasticity\",\n      \"description\": \"This program encompasses the molecular systems mediating bidirectional communication between neurons and glial cells, including formation and stabilization of synaptic contacts, activity-dependent signaling, and metabolic coupling. Key components include synaptic adhesion molecules (TENM4, CNTN1) that establish neural circuits and specify synapse identity, neurotrophic growth factors (BDNF signaling through NTRK2, NRG3 signaling through ErbB receptors) that support neuronal survival and synaptic function, cell adhesion molecules enabling heterophilic neuron-glia contacts, and metabolic factors supporting neuronal energy demands. Within the tumor microenvironment, neuron-tumor crosstalk becomes paramount, with tumor cells hijacking synaptic signaling machinery to enhance proliferation and invasion while simultaneously driving peritumoral neuronal hyperexcitability and seizures.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Synaptic adhesion molecule-mediated contact formation\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"Neurons in peritumoral cortex form direct excitatory electrochemical synapses with surrounding tumor cells\"\n            },\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"TENM4 involved in synapse specification and stability regulated by neuronal activity\"\n            },\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Cell adhesion molecules including CNTN1 mediate neuron-glia interactions essential for synaptic function\"\n            }\n          ],\n          \"genes\": [\"TENM4\", \"CNTN1\"]\n        },\n        {\n          \"name\": \"Neurotrophic growth factor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"BDNF signaling through NTRK2 regulates neuronal firing properties and synaptic transmission\"\n            },\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"BDNF-TrkB signaling supports neuronal survival and synaptic plasticity\"\n            },\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"NRG3 serves as glial-derived growth factor activating ErbB receptors on neurons\"\n            }\n          ],\n          \"genes\": [\"NTRK2\", \"NRG3\", \"LIFR\"]\n        },\n        {\n          \"name\": \"Astrocytic metabolic support to neurons\",\n          \"citations\": [\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Astrocytes supply lactate and glutamine to neurons, participate in glutamate-glutamine cycle essential for synaptic function\"\n            }\n          ],\n          \"genes\": [\"SLC1A3\", \"SLC1A4\", \"GLUD1\"]\n        },\n        {\n          \"name\": \"Tumor-associated seizure susceptibility\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"Peritumoral neurons show specific transcriptional alterations involving genes regulating neuronal homeostasis and synaptic plasticity that correlate with seizure susceptibility\"\n            }\n          ],\n          \"genes\": [\"KCNQ5\", \"KCNN3\", \"NTRK2\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Synaptic contacts between neurons and tumor cells\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"Direct synaptic contacts observed between peritumoral neurons and tumor cells with exchange of neurotransmitters\"\n            }\n          ],\n          \"genes\": [\"TENM4\", \"CNTN1\", \"NTRK2\"]\n        },\n        {\n          \"name\": \"Astrocyte-neuron metabolic interface\",\n          \"citations\": [\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Specialized astrocytic processes maintain close contact with neuronal synapses enabling metabolic exchange\"\n            }\n          ],\n          \"genes\": [\"SLC1A3\", \"SLC1A4\", \"GLUD1\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced neuron-tumor crosstalk driving bidirectional signaling that promotes tumor proliferation and neuronal hyperexcitability\",\n        \"Dysregulated trophic support from tumor cells and reactive astrocytes affecting neuronal properties\",\n        \"Altered synaptic plasticity in peritumoral neurons through dysregulated BDNF/NTRK2 and NRG3/ErbB signaling\",\n        \"Compromised astrocytic metabolic support to neurons due to metabolic competition from tumor cells\",\n        \"Enhanced seizure susceptibility through altered intrinsic neuronal properties and disturbed extracellular homeostasis\",\n        \"Peritumoral neuronal hyperexcitability driving tumor cell proliferation and invasion through activity-dependent signals\"\n      ],\n      \"evidence_summary\": \"The neuron-glial interaction program represents one of the most recently appreciated mechanisms driving astrocytoma progression and tumor-associated complications. Mounting evidence demonstrates that peritumoral neurons form direct synaptic contacts with tumor cells, with the tumor cells receiving direct excitatory input that drives proliferation and invasion. This neuron-tumor crosstalk is bidirectional: peritumoral neurons receive growth factors and metabolites from both astrocytes and tumor cells, which can either support their survival or drive hyperexcitability. The characterization of tumor-associated seizures (TAS) reveals specific transcriptional alterations in peritumoral neurons involving genes regulating synaptic transmission and plasticity, and the presence of eight genes in the input list related to neuron-glia interactions indicates comprehensive dysregulation. The NTRK2 gene is particularly significant in this context, as it normally transduces neurotrophic signals supporting neuronal survival and plasticity, but in the context of fusion-driven gliomas, becomes a constitutive driver of tumor proliferation that simultaneously affects peritumoral neuronal function through altered growth factor signaling.\",\n      \"significance_score\": 0.91,\n      \"citations\": [\n        {\n          \"source_id\": \"3\",\n          \"notes\": \"Detailed characterization of neuron-tumor crosstalk in peritumoral cortex showing direct synaptic contacts and altered neuronal properties\"\n        },\n        {\n          \"source_id\": \"40\",\n          \"notes\": \"Role of synaptic adhesion molecules and growth factor signaling in neuron-glia interactions\"\n        },\n        {\n          \"source_id\": \"45\",\n          \"notes\": \"Astrocytic metabolic support to neurons and altered support in tumor contexts\"\n        }\n      ],\n      \"supporting_genes\": [\"TENM4\", \"CNTN1\", \"NTRK2\", \"NRG3\", \"LIFR\", \"SLC1A3\", \"SLC1A4\", \"GLUD1\", \"KCNQ5\", \"KCNN3\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"BDNF\", \"NT-4\", \"ErbB2, ErbB3, ErbB4\", \"Neuregulin-1\", \"Synaptotagmin\", \"VAMP\", \"SNARE proteins\", \"Synaptophysin\", \"Synapsin\"],\n        \"citations\": [\n          {\n            \"source_id\": \"3\",\n            \"notes\": \"Multiple synaptic machinery components required for functional neuron-tumor synapses\"\n          },\n          {\n            \"source_id\": \"40\",\n            \"notes\": \"Complete set of neurotrophic signaling components needed for full trophic support\"\n          }\n        ]\n      }\n    }\n  ],\n  \"method\": {\n    \"clustering_basis\": [\n      \"Biological pathway databases (KEGG, Reactome) showing shared pathway participation\",\n      \"Functional annotations from gene ontology indicating shared biological processes\",\n      \"Co-citation analysis from search results identifying genes discussed in similar contexts\",\n      \"Known protein-protein interactions and pathway crosstalk\",\n      \"Expression patterns in astrocytes and gliomas from literature\"\n    ],\n    \"notes\": \"Gene programs were identified by systematic clustering of input genes based on shared participation in biological pathways, cellular processes, and responses to disease states. Each program represents a cohesive set of genes whose products cooperate to execute a specific cellular function or adaptive response. The classification prioritizes programs most relevant to astrocytoma pathophysiology, with emphasis on known mechanisms of tumor-microenvironment interaction and dysregulation of normal astrocytic support functions. Programs are ranked by significance based on number of supporting genes, strength of literature evidence, and direct relevance to astrocytoma disease mechanisms.\"\n  },\n  \"version\": \"1.0\"\n}\n```\n\n## Detailed Discussion of Emerging Evidence and Therapeutic Implications\n\n### Cross-Program Regulatory Hubs and Therapeutic Opportunities\n\nThe ten gene programs identified in this analysis are not functionally isolated but rather extensively interconnected through shared signaling nodes and regulatory mechanisms. For example, the glutamate signaling program (Program 1) directly impacts the ion channel homeostasis program (Program 3) through the dependence of SLC1A3 glutamate transport on the sodium gradients maintained by ATP1A2. Similarly, the receptor tyrosine kinase signaling program (Program 6) converges with the cytoskeletal dynamics program (Program 5) through MAPK signaling, which phosphorylates multiple regulators of Rho GTPases and actin dynamics[27][40][41][43]. The reactive astrocyte phenotype program (Program 9) can be triggered by both TLR4 activation through Program 9 and by chronic metabolic dysfunction through Program 8, creating feedback loops where initial metabolic stress drives reactive transformation, which then further compromises metabolic function[44][45].\n\nThese interconnected programs suggest that single-target therapeutic approaches may have limited efficacy in astrocytoma, as blocking one pathway through compensatory mechanisms often activates alternative pathways. Recent evidence from pediatric high-grade gliomas directly demonstrates this principle: when NTRK2 is knocked out in engineered tumor cells, downstream signaling is substantially reduced, but the tumor cells rapidly activate alternative oncogenic drivers including FLT1, c-KIT, VEGFR2, and other receptor tyrosine kinases[2][27][41]. This pathway plasticity is not random but rather reflects the activation of genes that converge on the same downstream effectors (MAPK, PI3K, JAK/STAT pathways) as the original driver[2][27][41]. Future therapeutic strategies should consider combination approaches targeting multiple programs simultaneously, or targeting central hubs that coordinate multiple pathways.\n\n### Aging, Senescence, and the Pre-Malignant Microenvironment\n\nOne emerging theme across multiple programs is the role of cellular senescence in creating a pro-tumorigenic microenvironment. The metabolic function program (Program 8) is directly connected to senescence through ITPR2-mediated calcium dysregulation, which drives mitochondrial dysfunction, ROS accumulation, and activation of senescence pathways[17]. Senescent cells adopt a characteristic phenotype including proliferative arrest coupled with upregulation of pro-inflammatory cytokines and growth factors, which remarkably overlaps with the reactive astrocyte phenotype (Program 9)[17][44]. In aging brains predisposed to glioma development, accumulation of senescent astrocytes could create an increasingly permissive microenvironment for malignant transformation through chronic production of pro-tumorigenic factors[17][44]. This connection between senescence and reactive astrocyte phenotype suggests that targeting senescence through inhibition of CypD (Cyclophilin D), a regulator of the mitochondrial permeability transition pore, might simultaneously address both metabolic dysfunction and chronic inflammatory phenotype in peritumoral astrocytes[17].\n\n### Therapeutic Targeting of Astrocyte Support Functions\n\nAn alternative therapeutic strategy, distinct from direct tumor targeting, would involve enhancing rather than inhibiting specific astrocytic support functions to improve the resilience of peritumoral neurons. The glutamate signaling program (Program 1) and the neuron-glial interaction program (Program 10) converge on the astrocyte's capacity to support neuronal function through glutamate-glutamine cycling. Enhancing glutamate transporter capacity in peritumoral astrocytes through genetic or pharmacological approaches might reduce glutamate excitotoxicity and tumor-associated seizures while simultaneously reducing the pro-tumorigenic effects of glutamate on tumor cells[3][45]. Similarly, enhancing astrocytic metabolic support through increased lactate production or enhanced provision of glutamine might improve peritumoral neuronal resilience to the tumor microenvironment[45]. These \"supporting the supporter\" approaches would represent fundamentally different therapeutic paradigms compared to traditional anti-tumor approaches.\n\n### Integration of Gene Programs with Spatial Tissue Architecture\n\nThe gene programs identified in this analysis operate within specific tissue contexts and spatial domains. The aquaporin-mediated water transport program (Program 2) is particularly localized to astrocyte end-feet at the perivascular interface[6][9][26][43]. The cell adhesion and polarity program (Program 4) functions to organize and maintain these perivascular astrocyte domains, and recent work demonstrates that loss of plexin-B1-mediated Rho signaling results in disorganization of astrocyte structure and loss of proper alignment[43]. Within astrocytomas, this spatial organization is profoundly disrupted, with peritumoral astrocytes losing their organized architecture and adopting a more migratory phenotype[26][43]. This spatial disorganization has direct consequences for barrier function, metabolic support to neurons, and the efficacy of drug delivery into tumors. Understanding the spatial organization of gene programs offers new opportunities for therapeutic intervention targeting the restoration of barrier architecture while simultaneously reducing tumor-supporting functions.\n\n---\n\n## Conclusion: Integrating Gene Programs into Comprehensive Astrocytoma Biology\n\nThe ten gene programs identified in this comprehensive analysis collectively capture the dysregulated molecular systems that characterize astrocytomas and their peritumoral microenvironments. These programs reflect both aberrant reactivation of normal developmental processes (such as Rho-dependent migration and morphological changes during reactive astrocyte transformation) and fundamentally novel interactions between tumor cells and the nervous system (such as tumor-induced neuronal hyperexcitability through seizure-generating mechanisms and direct neuron-tumor synaptic contacts).\n\nThe presence of overlapping genes across multiple programs emphasizes the integrative nature of cellular biology. For example, NTRK2 participates in both the receptor tyrosine kinase signaling program and the neuron-glial interaction program, representing a critical junction where tumor oncogenic signaling directly impinges upon normal neuron-glial communication systems. Similarly, calcium dysregulation through ITPR2 connects the ion channel homeostasis program with metabolic dysfunction and senescence pathways, indicating that calcium signaling represents a central regulatory node worthy of therapeutic attention.\n\nThe comprehensive mapping of these gene programs onto astrocytoma pathophysiology provides a foundation for systematic therapeutic development. Rather than viewing astrocytoma as a disease of tumor cell mutation and proliferation alone, the gene program analysis reveals astrocytoma as a disease of dysregulated cellular programs affecting tumor cells, peritumoral astrocytes, peritumoral neurons, immune cells, and the extracellular matrix. This systems-level perspective suggests that the most effective therapeutic approaches will likely target multiple programs simultaneously, potentially through combination therapies that address both tumor intrinsic properties and the dysregulated microenvironment. The presence of near-complete pathway components within the input gene list for most programs indicates that comprehensive dysregulation across entire systems is characteristic of astrocytoma, making multi-target approaches not merely advisable but necessary for overcoming the redundancy and plasticity that currently limit single-agent therapeutic efficacy.",
    "citations": [
      "https://www.nature.com/articles/s41698-025-01151-w",
      "https://www.nature.com/articles/s41698-025-01190-3",
      "https://www.nature.com/articles/s41467-025-66226-5",
      "https://www.ncbi.nlm.nih.gov/gene/23627",
      "https://www.ncbi.nlm.nih.gov/gene/7178",
      "https://www.ncbi.nlm.nih.gov/gene/361",
      "https://www.ncbi.nlm.nih.gov/gene/1499",
      "https://www.ncbi.nlm.nih.gov/gene/20512",
      "https://www.ncbi.nlm.nih.gov/gene/6506",
      "https://www.ncbi.nlm.nih.gov/gene/25240",
      "https://www.ncbi.nlm.nih.gov/gene/211323",
      "https://www.nature.com/articles/s42003-025-08959-z",
      "https://www.ncbi.nlm.nih.gov/gene/21898",
      "https://www.ncbi.nlm.nih.gov/gene/12064",
      "https://www.ncbi.nlm.nih.gov/gene/7099",
      "https://www.nature.com/articles/s41514-025-00291-4",
      "https://www.ncbi.nlm.nih.gov/gene/18018",
      "https://www.ncbi.nlm.nih.gov/gene/2697",
      "https://www.ncbi.nlm.nih.gov/gene/16971",
      "https://www.ncbi.nlm.nih.gov/gene/15903",
      "https://www.ncbi.nlm.nih.gov/gene/3725",
      "https://www.ncbi.nlm.nih.gov/gene/19",
      "https://www.ncbi.nlm.nih.gov/gene/3398",
      "https://www.ncbi.nlm.nih.gov/gene/21825",
      "https://www.nature.com/articles/s41467-025-66985-1",
      "https://www.ncbi.nlm.nih.gov/gene/18033",
      "https://pubmed.ncbi.nlm.nih.gov/41390476/?fc=None&ff=20251214123318&v=2.18.0.post22+67771e2",
      "https://www.ncbi.nlm.nih.gov/gene/1432",
      "https://www.ncbi.nlm.nih.gov/gene/4790",
      "https://www.ncbi.nlm.nih.gov/gene/2670",
      "https://www.ncbi.nlm.nih.gov/gene/24387",
      "https://www.ncbi.nlm.nih.gov/gene/3655",
      "https://www.nature.com/articles/s41467-025-65582-6",
      "https://www.ncbi.nlm.nih.gov/gene/16403",
      "https://www.nature.com/articles/s41467-025-62721-x",
      "https://www.ncbi.nlm.nih.gov/gene/5156",
      "https://www.nature.com/articles/s42003-025-09169-3",
      "https://www.nature.com/articles/s41467-025-65095-2",
      "https://www.nature.com/articles/s42003-025-09138-w",
      "https://www.nature.com/articles/s42003-025-09122-4",
      "https://www.nature.com/articles/s42003-025-09270-7",
      "https://www.nature.com/articles/s41380-025-03421-2",
      "https://www.ncbi.nlm.nih.gov/gene/1894",
      "https://www.ncbi.nlm.nih.gov/gene/7422",
      "https://www.nature.com/articles/s41598-025-26426-x",
      "https://www.ncbi.nlm.nih.gov/gene/6667",
      "https://www.ncbi.nlm.nih.gov/gene/22339",
      "http://json-schema.org/draft-07/schema#\","
    ],
    "duration_seconds": null
  }
}